

# CONGENITAL CARDIOLOGY TODAY

Timely News and Information for BC/BE Congenital/Structural Cardiologists and Surgeons

Volume 10 / Issue 4

April 2012

North American Edition

## IN THIS ISSUE

### Expanding the Role of Percutaneous Pulmonary Valve Implantation

by Sara M. Trucco, MD and Jacqueline Kreutzer, MD  
~Page 1

### Effect of Endotracheal Suctioning on Dynamic Lung Compliance after Manual Hyperinflation in Mitral Valve Replacement Surgery Patients

by Nizamuddin, MPT; Faizan Ahmed, MPT; Muhammed Abid Geelani, MD, MCH; Jamal Ali Moiz, MPT, PhD  
~Page 13

## DEPARTMENTS

### Medical News, Products and Information

~Page 20

### June Medical Meeting Focus

~Page 21

## UPCOMING MEDICAL MEETINGS

### PICS ~AICS

April 15-18, 2012; Chicago, IL USA  
[www.picsymposium.com](http://www.picsymposium.com)

### Update in Congenital Heart Management

April 17, 2012; Dubai, UAE  
contact Alan Weisman -  
[aweisman@childrensnational.org](mailto:aweisman@childrensnational.org)

### World Congress of Cardiology Scientific Sessions 2012

April 18-20, 2012; Dubai, UAE  
[www.worldcardiocongress.org](http://www.worldcardiocongress.org)

CARDIOSTIM 2012 - Cardiac Electrophysiology & Cardiac Techniques  
June 13-16, 2012, Nice, France  
[www.cardiostim.com](http://www.cardiostim.com)

See website for additional meetings

## CONGENITAL CARDIOLOGY TODAY

Editorial and Subscription Offices  
16 Cove Rd, Ste. 200  
Westerly, RI 02891 USA  
[www.CongenitalCardiologyToday.com](http://www.CongenitalCardiologyToday.com)

© 2012 by Congenital Cardiology Today ISSN: 1544-7787 (print); 1544-0499 (online).  
Published monthly. All rights reserved.

Recruitment Ads on pages:  
8, 11, 16, 17, 18, 21, 22, 23

## Expanding the Role of Percutaneous Pulmonary Valve Implantation

By Sara M. Trucco, MD and  
Jacqueline Kreutzer, MD

### Introduction

Right Ventricular Outflow Tract (RVOT) dysfunction with progression of pulmonary stenosis and insufficiency is a challenging problem that occurs often following repair of various forms of congenital heart disease.<sup>1</sup> Although surgical revision of the RVOT is associated with low morbidity and mortality,<sup>2,3</sup> the limited lifespan of the surgical implants (right ventricle to pulmonary artery homografts, valved conduits and bioprosthetic valves) subjects these patients to multiple open-heart procedures,<sup>4,5</sup> with significant cumulative morbidity. In the 1990's, bare-metal stenting was introduced as an option to prolong conduit longevity.<sup>6</sup> Although stent implantation is an effective means of reducing conduit stenosis, this is achieved at the expense of free pulmonary valve insufficiency. The long-term deleterious effects of chronic severe pulmonary valve insufficiency are well-known, leading to decreased exercise capacity, fatal arrhythmias and progressive right ventricular (RV) failure.<sup>7-9</sup> Percutaneous pulmonary valve (PPV) implantation offers a minimally invasive approach to address RVOT dysfunction without the resulting pulmonary insufficiency.

The first PPV was designed and implanted by Dr. Phillip Bonhoeffer in the year 2000.<sup>10,11</sup> This design, with subsequent modifications, was later adopted for the development of the Melody Valve™, which is currently commercially available through Medtronic (Figure 1). The Melody Valve™




Figure 1 A & B: Melody Valve™ (A). 20 mm Ensemble® Balloon Delivery System (B) with valve crimped and loaded (B).

consists of a bovine jugular venous valve sewn into a platinum iridium stent, and was the first percutaneous valve approved for human use in the United States by the Food and Drug Administration (January of 2010).<sup>12</sup> Specifically,

### Need to Recruit a Pediatric Cardiologist?

Advertise in Congenital Cardiology Today, the only monthly newsletter dedicated to pediatric and congenital cardiologists.

Reach the most Board Certified or Board Eligible pediatric cardiologists worldwide.

Recruitment advertising includes full color in either the North American print edition, or the electronic PDF International edition.

Available in 1/3 and 1/2 page vertical Recruitment ad sizes. We can create the advertisement for you at no extra charge!

**Contact:** Tony Carlson, Founder  
Tel: +1.301.279.2005 or [TCarlsonmd@gmail.com](mailto:TCarlsonmd@gmail.com)



# SIZING UP THE FUTURE



## **X™ Line PTV Balloon Dilatation Catheters**

*Braided inner tubing and radiopaque marker bands for maintaining strength & trackability*

## **PTS® Sizing Balloon Catheters**

*For accurate measurement of selecting the appropriately sized occluder device*

## **NuCLEUS-X™**

### **PTV Balloon Dilatation Catheters**

*Variable waist expansion in the center of the balloon for accurate placement*



**The Center  
of It All**



**B|BRAUN**

*Interventional  
Systems*

B. Braun Interventional Systems Inc.  
824 Twelfth Avenue  
Bethlehem, PA 18018  
Tel: 1-877-VENA CAV (836-2228)  
Fax: 610-266-3982

[www.bisusa.org](http://www.bisusa.org)




Figure 2 A & B: (A) Selective coronary angiography performed in long axial oblique projection with simultaneous conduit balloon dilation in a patient with a single left coronary artery (black arrow) and anomalous right coronary artery crossing the right ventricular outflow tract. With the balloon inflated, the left coronary fills but flow to the right coronary artery is completely occluded (white arrow). (B) With deflation of the balloon, blood flow is restored to the right coronary artery (white arrow). This is a contraindication for Melody Valve™ implantation.

the Melody Valve™ is approved in the USA as a humanitarian device for use in dysfunctional conduits with an original implantation size of at least 16 mm in diameter, with either a mean gradient of 35 mmHg or at least moderate pulmonary valve insufficiency. PPV implantation is considered a Class II AHA recommendation for conduits with moderate to severe stenosis or insufficiency provided the patient meets the inclusion/exclusion criteria for the available valve (Level of evidence B) as per recent Scientific Statement from the American Heart Association on indications for cardiac catheterization and intervention in pediatric cardiac disease (*Circulation*. 2011;123:2607-2652). In the last ten years, PPV implantation has quickly changed the treatment of RVOT dysfunction, and is currently performed in over 150 centers worldwide with more than

3,000 patients treated.<sup>13</sup> This article reviews the common use of the Melody Valve™ and explores innovative uses that remain to be further studied.

### Morphologic Considerations

When hemodynamic inclusion criteria is met, the size and shape of the RVOT, as well as its proximity to the coronary arteries, must also be evaluated prior to PPV implantation. The RVOT will need to measure between 16 and 22 mm to accommodate the Melody Valve™. Morphologically, a straight or hourglass-shaped conduit is more favorable for Melody Valve™ implantation than a divergent or pyramidal shape,<sup>14</sup> but shape rarely precludes implantation. Additionally, the anatomy and course of the coronary arteries in relation to the RVOT must be determined. In cases where the coronaries arise anomalously or appear to course in proximity of the conduit, selective coronary angiography with simultaneous conduit balloon dilation must be performed (Figure 2) to prevent coronary compression with stent placement.<sup>16, 17</sup>

An accommodating RVOT morphology is critical to successful Melody Valve™ implantation, and thus preparing an adequate “landing zone” has become a key component of the procedure. This is particularly true in patients in whom the predominant indication for PPV implantation is stenosis, as these conduits often become narrow and stiff over time. In these patients, the RVOT is prepared by sequential angioplasties and stent

implantations within the conduit, often with use of ultra-high pressure balloons. Once the target diameter has been achieved, implantation of the Melody Valve™ is a relatively simple component of the procedure.

Table 1 summarizes our experience at Children’s Hospital of Pittsburgh and illustrates the change in conduit diameter achieved with bare metal stenting and eventual Melody Valve™ implantation. On average, the conduits had narrowed by 30 to 33% of their original size. All but one patient required pre-stenting with a bare metal stent, which expanded the conduit by an average of 13% in the AP view, and 29% in the lateral projection. Melody Valve™ implantation further expanded the area by an average of 10 to 13% (Table 1).

### Typical indication: Percutaneous Melody Valve™ implantation for Combined Conduit Stenosis and Insufficiency

#### Clinical History

The patient is a 16-year-old female with truncus arteriosus type I. She underwent full repair in the neonatal period with placement of a 13 mm RV to PA conduit. Five years later, she underwent conduit revision with placement of a 21 mm homograft and left pulmonary arterioplasty. During the six months prior to cardiac catheterization, the patient had progressive worsening of symptoms including exercise intolerance, shortness of breath, chest pain, palpitations, recurrent migraines and generalized lethargy. She reported these

**Table 1: Biplane Dimensions of the Conduits Before and After Intervention in Our Patient Population**

Patient (#)	Original Conduit/ Valve Size (mm)	Pre-Stent AP Diameter (mm)	Pre-Stent Lateral Diameter (mm)	Total RVOT Stents (#)	Post-Stent AP Diameter (mm)	Post-Stent Lateral Diameter (mm)	Post-Melody AP Diameter (mm)	Post-Melody Lateral Diameter (mm)
1	25	13.2	16.7	2	15	18.5	18	20.2
2	24	17	14.8	2	16.1	17	19.2	19.8
3	22	14.9	10.71	2	15.8	16.2	16.9	19.9
4	17	10.3	12.76	1	18	15.1	15.9	16.3
5	18	14.4	9.5	1	12.9	14	17.9	17.6
6	25	16	14.1	2	19	18.3	19	18.6
7	25	16.5	12.1	2	16.6	17.5	21.3	20.7
8	17	13.7	15.2	1	17.5	18.8	18.2	18.3
9	24	17	14.4	2	17.6	18.1	20	21.6
10	22	15.3	17.3	1	16.6	19.7	17.9	20.9
11	20	14.7	16.7	1	15.3	18.4	19.9	19.9
12	22	11.4	11.6	2	16.6	18.3	17.5	19.5
13	19	16.2	16	1	16.7	18.8	17.4	19.4
14	21	14.3	10.3	3	15.6	16.6	18.2	20
15	21	17	17.2	2	17	18.4	20.8	19.8
16	25	19.1	21.9	0	x	x	19	21
17	17	14.8	13.7	2	17.9	18.1	16.5	17.1
18	18	14.7	11.9	2	16	17	18	17.7

Note that most conduits are not perfectly round. The most gain in diameter is achieved with bare metal stenting. Minimal further expansion occurs with Melody valve implantation. In general, the ending dimensions tend to be slightly smaller than those of the original diameter of the surgical conduit.






Figure 3: Main pulmonary artery angiogram performed in lateral projection reveals a narrowed conduit (white arrow) with free pulmonary valve insufficiency. The conduit measures 14.3 mm by 10.3 mm. There is bilateral-branch pulmonary artery stenosis (black arrow), affecting the right pulmonary artery (\*) greater than left (LPA).




Figure 4: Aortic root (Ao) angiography demonstrates mild truncal valve insufficiency and normal origin of the right (white arrow) and left (black arrow) coronary arteries. The course of the coronary arteries and branches is not in proximity to that of the right ventricle to pulmonary artery conduit.

symptoms with casual walking and while climbing one flight of stairs, rendering her New York Heart Association Class II to III. Echocardiogram revealed moderate conduit stenosis and insufficiency, a mildly dilated RV with preserved systolic function, and bilateral branch PA stenosis, right greater than left. Her truncal valve had mild insufficiency. The peak gradient through the conduit was 72 mmHg with a mean gradient of 40 mmHg. Cardiac MRI confirmed the moderate conduit stenosis and insufficiency, with a regurgitant fraction of 41%. Given her significant symptoms and imaging findings, she was referred for cardiac




Figure 5: Simultaneous inflation of a 16 mm X 4 cm BIB balloon and 26 mm EV3 Max LD stent in the LPA and a 14 mm X 4 cm BIB balloon in the previously placed EV3 Max LD stent in the RPA. There remains a mild waist in the LPA stent (arrow).




Figure 6: Melody Valve™ (arrow) implantation into the RV to PA conduit using a 20 mm Ensemble® Balloon Delivery System.

catheterization to undergo PPV implantation using the Medtronic Melody Valve™ along with branch pulmonary artery rehabilitation.

#### Cardiac Catheterization Procedure

The patient was placed under general anesthesia and access was obtained in the right femoral artery and vein. The patient was heparinized and a full right and left heart cardiac catheterization was performed for hemodynamic and angiographic evaluation. The RV systolic pressure was 60 mmHg or  $\frac{2}{3}$  systemic, with a 40mmHg peak to peak gradient into the main pulmonary artery (MPA), thus meeting hemodynamic criteria for conduit replacement or Melody Valve™ implantation.<sup>15</sup> There was a further 7mmHg gradient into the right pulmonary artery (RPA) with no gradient into the left. The MPA diastolic pressure was low with a




Figure 7: Post-dilation of the Melody Valve™ with a 20 mm X 2 cm ATLAS® balloon.

ventricularized tracing, consistent with free pulmonary insufficiency. The cardiac index was normal (3.3 L/m/m<sup>2</sup>) with no evidence of intracardiac shunting. Angiography showed a calcified and narrow conduit measuring 14.3 mm by 10.3 mm with free insufficiency filling a mildly dilated RV. The branch pulmonary arteries demonstrated significant narrowing at the proximal RPA and mild narrowing of the proximal left pulmonary artery (LPA) (Figure 3). Aortic root angiography revealed mild truncal valve insufficiency and normal coronary arteries whose course did not come near the RV to PA conduit (Figure 4). Given the finding of bilateral branch PA stenosis, a second venous sheath was placed in the left femoral vein.

RPA angioplasty was performed using a 12 mm X 2 cm ATLAS® balloon catheter. Despite full expansion of the balloon, repeat angiography demonstrated significant recoil. The RPA branch stenosis was then treated with a 26 mm long EV3 Max LD Intrastent hand-crimped onto a 14 mm X 4 cm balloon-in-balloon (BIB) catheter. Repeat angiography showed complete resolution of the RPA stenosis.

Attention was then turned to the LPA. A second 26 mm long EV3 Max LD Intrastent was hand-crimped onto a 16 mm X 4 cm BIB balloon and expanded in the proximal LPA with simultaneous inflation of the 14 mm X 4 cm BIB balloon in the previously placed RPA stent (Figure 5). This resulted in relief of the branch RPA and LPA stenosis without stent compression or protrusion into the RV to PA conduit.

Having completed the branch pulmonary artery rehabilitation, attention was then turned to the RV to PA conduit. Compliance testing had revealed significant recoil of the conduit, and therefore pre-stenting prior to Melody Valve™ implantation was undertaken. Additionally, pre-stenting has been shown to reduce the occurrence of PPV stent fractures, the leading cause of PPV reintervention.<sup>16, 17</sup> A 26 mm long EV3 Mega LD Intrastent was hand crimped onto a 18 mm X 4.5




Figure 8 A, B & C: Following interventions main pulmonary artery angiogram demonstrates no significant pulmonary valve insufficiency (A). A right ventriculogram (B & C) demonstrates no residual conduit stenosis and unobstructed distal flow into the bilateral branch pulmonary arteries. RV: Right ventricle; \* Main pulmonary artery.

cm BIB balloon and expanded into the stenotic waist of the RV to PA conduit. Great care was taken to avoid jailing of the previously placed RPA and LPA branch stents. As stent recoil was observed in the lateral projection, further stenting was undertaken with placement of two Cordis Palmaz XL 10 mm X 30 mm stents. The RV to PA conduit stents were then further dilated with an 18 mm X 2 cm ATLAS® balloon. Repeat angiography showed significant improvement in the conduit stenosis. The Melody Valve™ was then implanted using a 20 mm Ensemble® Balloon Delivery System (Figure 6) and post dilated with a 20 mm ATLAS® balloon to full expansion (Figure 7).

Following PPV implantation, angiography demonstrated no pulmonary insufficiency and resolution of the conduit stenosis (Figure 8). The RV systolic pressure dropped to 36 mmHg, or 1/3 systemic, with no significant gradient across the Melody Valve™ stent. There remained a minor gradient into the branch pulmonary arteries, though distal mean PA pressures rose from 12 mmHg to 17 mmHg.

#### Follow-up

The patient tolerated the procedure well without complication and was discharged home the following morning. She reported mild procedural groin and chest pain, which resolved within a week of the procedure. Discharge echocardiography demonstrated normal biventricular function with minimal pulmonary stenosis (mean gradient of 8 mmHg) and trivial pulmonary insufficiency.

At six months follow-up, the patient reports an improvement in her stamina with increase in her energy level and significant reduction in her migraine frequency. Echocardiogram reveals normal RV systolic function with normal RV systolic pressure (25 mmHg plus RA pressure by tricuspid regurgitation jet). There is minimal pulmonary stenosis (peak gradient of 18 mmHg, mean of 9 mmHg) and trivial pulmonary insufficiency. The branch PAs are not well seen by transthoracic imaging; however, color Doppler demonstrates no significant stenosis. Fluoroscopy of the valve reveals no stent fractures.

#### Expanding the Role of the Melody Valve™: Non-Conventional Delivery Approaches / Indications

Only approximately 15% of potential patients with RVOT dysfunction can accommodate the currently approved implantable valves.<sup>18</sup> Many patients remain poor Melody Valve™ candidates due to their small physical size, limited vascular access, or the size and shape of their RVOT. These limitations have led some physicians to explore innovative, off-label techniques utilizing the Melody Valve™. Additionally, alternative PPV stents are being designed in hopes of treating both large and small RVOT morphologies.

An RVOT greater than 22 mm is a contraindication for Melody Valve™ implantation due to the risk of dislodgement.<sup>1</sup> Additionally, a prior RVOT patch repair is considered a relative contraindication to PPV implantation due to the unfavorable resulting morphology identified in

early studies.<sup>14, 19</sup> More recently, pre-stenting with bare-metal stents has been reported as a way to “prime” the RVOT in patients with prior RVOT patch repair, thus permitting subsequent successful PPV implantation.<sup>20</sup> In patients with large and distensible RVOT conduits, a hybrid approach combining intra-operative PPV implantation with simultaneous conduit downsizing has been undertaken with some success.<sup>21</sup> Alternatively, Melody Valve™ implantation into the bilateral branch pulmonary arteries has been proposed as a minimally invasive, though still experimental, option in patients with large and insufficient conduits.<sup>22, 23</sup> Heterotopic implantation of the Melody Valve™ has since expanded, with recent reports of its use in the tricuspid valve position in patients with both single ventricle and two ventricle physiologies.<sup>24-26</sup> In recent months, a small series describing the use of the Melody Valve™ in the aortic and mitral positions has been reported.<sup>27</sup> It should be noted that implantation of the Melody Valve™ in the aortic position does require device modification and extreme care, so to not occlude the coronary ostia with the covered portion of the stent. Although preliminary, the short-term results of this series were promising, and demonstrated durability of the Melody Valve™ function despite exposure to the high-pressure hemodynamics of the systemic circulation.<sup>27</sup>

On the opposite end of the spectrum are small patients whose physical size may not accommodate a 22 French delivery system and those whose conduit measures less than 16 mm in diameter. Such small patients are not typical Melody Valve™ candidates.<sup>12</sup> However,



18th WORLD CONGRESS  
Cardiac Electrophysiology & Cardiac Techniques  
**JUNE 13 >16 | 2012 NICE • FRENCH RIVIERA**

Painting by Françoise Persillon

Reed Expositions

Cardiostim / Reed Expositions France - Phone: +33 (0)1 47 56 24 56 - Email: cardiostim@wanadoo.fr

**Deadline Early Bird Fees  
April 5, 2012**

**Register now on [www.cardiostim.com](http://www.cardiostim.com)**





hybrid procedures using the subxyphoid or per-ventricular approach have been successful in overcoming some of these limitations.<sup>21,28</sup> Fetal trans-apical bare metal stent implantation into the MPA has recently been described in an animal model, suggesting the possibility for prenatal PPV implantation in the future.<sup>29</sup> Direct intra-operative Melody Valve™ implantation is an alternative technique that has been used successfully in young infants, such as the case described below, allowing for serial balloon dilation of the valve as the child grows.

Pulmonary valve stent technology continues to evolve with the goal of treating a larger percentage of patients with RVOT dysfunction with the percutaneous technique. The Edwards SAPIEN™ transcatheter heart valve can be used in patients with larger RV to PA conduits, as it is sized as large as 26 mm.<sup>30</sup> The US Food and Drug Administration recently approved the use of the SAPIEN™ valve under the Human Device Exemption regulation for aortic indication. Self-expanding nitinol pulmonary valve stents offer the potential of treating larger RVOT morphologies with a low-profile design, but are still under investigation.<sup>18,31</sup> Custom PPVs designed to fit a patient's unique RVOT have also been described, with at least one successful human implantation, but are currently prohibitively expensive for routine use.<sup>32</sup> PPV options for small patients remain limited, though the implantation of a custom

handmade stent in an infant has been reported.<sup>33</sup>

### Example of Intraoperative Melody Implantation in an Infant

#### Clinical History

The patient is a female infant with Tetralogy of Fallot and Alagille Syndrome. Her cardiac disease was first diagnosed in the early neonatal period after evaluation of cardiac murmur by echocardiogram revealed mild to moderate pulmonary stenosis and a moderate-sized ventricular septal defect (VSD). At two months of age, follow-up echocardiography demonstrated progression of her lesion with severe pulmonary stenosis and infundibular narrowing. Her pulmonary arteries appeared severely hypoplastic, but could not be well visualized by ultrasound. At this time she was noted to have worsening jaundice, and thus underwent a full gastrointestinal evaluation, which included a liver biopsy. This revealed significant liver dysfunction consistent with Alagille Syndrome.

#### Cardiac Catheterization Procedures

She underwent her first cardiac catheterization at two months of age, to better delineate the anatomy of the pulmonary arteries prior to surgical repair. Angiography demonstrated a




Figure 9: Main pulmonary artery (MPA) angiography demonstrates severely hypoplastic branch pulmonary arteries with the LPA measuring 3.8 mm (black arrow) and the RPA measuring 2.5 mm (white arrow). The MPA is dilated.

diffusely hypoplastic RVOT with continuous, though small, pulmonary branches. She had a normal cardiac index of 3.6 L/m<sup>2</sup> with a Qp/Qs of 0.7 to 1 consistent with right to left intracardiac shunting. One week later, she was



## Pediatric Heart Failure Summit

Toronto • June 6-7, 2012

#### FACULTY

Paul F. Kantor MD • Steven E. Lipshultz MD • Luc L. Mertens MD  
Seema Mital MD • Daniel J. Penny MD • Andrew N. Redington MD  
Robert D. Ross MD • Robert Shaddy MD • Jeffrey A. Towbin MD  
Glen Van Arsdell MD • Steven Webber MD • Jay Wilkinson MD

Call for Pediatric Summit Abstracts is now open  
Visit [www.TorontoHeartSummit.com](http://www.TorontoHeartSummit.com)  
(Abstract deadline is February 18, 2012)

[www.sickkids.ca/centres/heart-centre](http://www.sickkids.ca/centres/heart-centre)



## A State of the Art Symposium on Pediatric Cardiomyopathy and Heart Failure

In conjunction with The 15th Annual Toronto Heart Summit  
held from June 7 to 9, 2012

**SickKids**  
THE HOSPITAL FOR  
SICK CHILDREN  
The Labatt Family  
Heart Centre




Figure 10 A and B: (A) Main pulmonary artery (\*) angiogram performed following implantation of two 7 mm X 12 mm Cook Formula premounted stents in the LPA (black arrow) and RPA (white arrow) demonstrates significant improvement in vessel diameter. (B) In lateral projection the free pulmonary valve insufficiency is appreciated through a dilated RVOT following surgical patch. The branch pulmonary arteries are improved in caliber with no residual stenosis.

taken to the operating room and underwent RVOT reconstruction with transannular patch augmentation extending to the PA bifurcation. Due to the small nature of her distal PA anatomy, it was felt that the VSD could not be closed at that time.

At four months of age, the patient was doing relatively well from a cardiac perspective, with oxygen saturations in the high 80's to low 90's, no evidence of heart failure or cyanosis, and steady weight gain. Her liver dysfunction,

however, had progressed significantly, raising concerns regarding the need for liver interventions including transplantation. As the unrepaired cardiac condition with right ventricular hypertension was a contraindication for liver transplantation, she was brought to the catheterization laboratory for pulmonary artery rehabilitation in hopes of rendering her a candidate for full cardiac surgical repair.

In the catheterization lab, hemodynamic evaluation revealed no gradient into the MPA, but significant gradients (60 to 65 mmHg) into the right and left pulmonary arteries. Her cardiac index was normal with a Qp/Qs of 1.37. Angiography demonstrated hypoplastic branch pulmonary arteries with the proximal RPA measuring 2.5 mm and the proximal LPA measuring 3.8 mm (Figure 9). Angioplasty did not succeed in resolving the stenosis, as there was marked vessel recoil, and thus, both proximal pulmonary arteries were stented with two 7 mm X 12 mm Cook Formula premounted stents respectively. Repeat angiography showed improvement in the caliber of both branch pulmonary arteries with normal flow to all branches (Figure 10). The gradient across the branch pulmonary arteries dropped to 22 mmHg to the RPA and 14 mmHg to the LPA. The cardiac index remained normal and the Qp/Qs rose significantly to 2.9. These hemodynamics were considered favorable for complete repair and closure of the ventricular septal defect, and therefore the patient was admitted to the cardiac ICU for observation prior to her full repair.

#### Melody Valve™ Insertion

In the days following her catheterization, the patient was discussed at our joint Cardiothoracic Surgery and Cardiology conference. The patient had severe pulmonary valve insufficiency secondary to the original surgical transannular patch. Although well-tolerated at the moment, the concern was raised that, given the high likelihood of needing liver transplantation, in the future, hemodynamics would have to be optimized. In addition, as the liver disease continues to progress, the patient would become high-risk for future cardiac bypass and pulmonary valve replacement. Finally, optimal hemodynamics would be necessary for survival at the time of future liver transplantation. Therefore, it was decided that the patient should undergo intraoperative Melody Valve™ insertion at the time of closure of the ventricular septal defect, to provide pulmonary valve function, optimize hemodynamics and allow for minimally-




Figure 11 A and B: Chest X-ray obtained following intraoperative Melody Valve™ implantation in antero-posterior (A) and lateral projections (B). Note that the proximal and distal edges of the Melody Valve™ (arrows) have been modified (folded over) to achieve a decrease in length. The branch PA stents are again seen and appear widely patent without fracture.

invasive serial dilations of the valve in the future as she grew.

One week after her bilateral pulmonary arterial stenting procedure, the patient was taken to the operating room for closure of the ventricular septal defect and Melody Valve™ insertion. She was placed under general anesthesia and the previous median sternotomy was incised. The heart was cannulated, the patient cooled to 35 degrees Celcius, and cardiopulmonary bypass was instituted. During the cross-clamp period, the ventricular septal defect was closed with patch material. The Melody Valve™ was crimped slightly using a 5 ml syringe, asymmetrically so that the distal end reached 16 mm in diameter, while the proximal end was wider, close to the original size. Then, it was positioned into the RVOT. In order to decrease the length for optimal fitting, Dr.

THE 23RD ANNUAL CONFERENCE OF THE WESTERN SOCIETY OF PEDIATRIC CARDIOLOGY  
CONTROVERSIES IN PEDIATRIC AND CONGENITAL CARDIOLOGY



JUNE 8 - 10, 2012

AT THE SCENIC SKAMANIA LODGE IN STEVENSON, WA

WWW.WSOPC.ORG





## Opportunities available in all facets of Pediatric Cardiology

HCA, the largest healthcare company in the US, owns and/or manages over 160 hospitals in 20 states. We have opportunities available for Pediatric Cardiologists, Cardiovascular Surgeons and specialties associated with Pediatric Cardiology in most of our markets.

Whether you are looking for your first position or somewhere to complete your career, chances are we have something that will fit your needs. Call or email today for more information.



Kathy Kyer

Pediatric Subspecialty Recruitment Manager

Kathleen.Kyer@HCAHealthcare.com

937.235.5890

Morell folded over the proximal and distal edges of the Melody Valve™ stent (Figure 11), which did not alter valve function and allowed the shortening of the valve so as to fit within the right ventricular outflow tract. Additional patch material was used to repair the RVOT further to provide an optimal anchor for the valve. The patient's atrial septal defect was then closed primarily using 5-0 Prolene. Transesophageal echocardiography showed preserved biventricular function with optimal Melody Valve™ function and no residual intracardiac shunts.

### Follow-Up

The patient tolerated the procedure well. Her post-operative recovery was complicated by the development of hemolysis, thought to be due to a tiny anterior paravalvular leak. She received a packed red blood cell transfusion and was started on pentoxifylline with good response. Approximately one week following surgery, the patient developed a fever and was found to have *Enterococcus Faecalis* growing from both peripheral and Broviac blood cultures. Given the proximity in time to her surgical repair, and the multiple stents and patch materials within her heart, the patient was treated for 6 weeks with IV antibiotics for presumed endocarditis, although endocarditis was never documented.

At six month follow-up, the patient is doing clinically well with no symptoms referable to the cardiovascular system. Echocardiogram reveals normal RV systolic function with normal RV systolic pressures by TR jet (23 mmHg). There is mild pulmonary stenosis and trivial pulmonary insufficiency. Her liver disease, for the moment, remains severe, but is being medically managed. The hemolysis is resolved.

### Concluding remarks

The development of PPV stents such as the Medtronic Melody Valve™ has quickly revolutionized the treatment of RVOT dysfunction. The pulmonary stenosis and insufficiency that previously required an open-heart procedure, can now be safely and effectively treated with minimally invasive percutaneous techniques.<sup>1,10,12</sup> Although a large percentage of patients with RVOT dysfunction do not currently meet morphologic criteria for PPV implantation, innovative techniques partnered with evolving stent technology offer hope that many more patients will benefit from PPV implantation in the near future.<sup>1, 8, 20, 30, 31</sup>

From our experience with Melody Valve™ implants, we have learned a few technical tips:

1. The key component of the procedure is successful preparation of a perfect landing zone for the valve. This is particularly difficult in stenotic, stiff and calcified conduits, but can also be tricky with compliant conduits. It is most difficult to predict how the conduits will respond to intervention, and thus, procedures tend to be of highly variable duration.
2. Stent recoil is common in stenotic conduits, particularly when positioned immediately underneath the sternum. Preparing the site for Melody Valve™ also implies minimizing the chances of PPV stent recoil, and thus, it may be necessary to use one or more stents with the highest hoop strength to assure optimal landing zone diameter.
3. The use of ultrahigh pressure balloons has been essential to achieve wide patency of the stented conduits, but should preferably be used prior to implantation of the valve itself. The effect that ultrahigh pressure dilation can have on the Melody Valve™ stent can be unpredictable (Figure 12).



### Help Congenital Cardiology Today Go Green!

**How:** Simply change your subscription changed from print to the PDF, and get it electronically.

**Benefits Include:** receiving your issue quicker; ability to copy text and pictures; hot links to authors, recruitment ads, sponsors and meeting websites, plus the issue looks exactly the same as the print edition.

**Interested?** Simply send an email to [Subs@CCT.bz](mailto:Subs@CCT.bz), putting "Go Green" in the subject line, and your name in the body of the email.






Figure 12 A-E: Right ventricular outflow tract angiogram following Melody Valve™ implantation demonstrates valve in good position (A). Note that the valve stent extends slightly into the right ventricular outflow tract proximally (arrows). There was a mild residual gradient. With the aim to eliminate the gradient, this patient underwent repeat dilation with ultrahigh pressure balloon (B & C). Note the shortening of the stent and stretching of the struts during inflation (arrows). Post dilation fluoroscopy and angiograms (D & E) showed significant Melody Valve™ stent recoil, as demonstrated by the narrower dimensions of the stent post dilation compared with that at maximal dilation. The residual gradient was unchanged. In this patient, post dilation of the valve with ultrahigh pressure balloon was of no benefit.

4. Most homografts are not compliant, but on occasion they can be. When stenosis is mild, compliance testing with an angioplasty balloon is essential to determine candidacy for Melody Valve™ implantation. If no waist is present at 20-22 mm dilation, Melody implantation is contraindicated as embolization will be highly likely.
5. Evaluation for risk of coronary artery compression should always be performed. Although there are obvious cases of coronary compression (Figure 2), there are times when this can be subtle, and difficult to interpret. One should consider that the external diameter that the old conduit will achieve after Melody Valve™ placement is likely larger than that at the time of compliance testing (one would have to add the wall thickness of the Melody Valve™ plus that of the stents used). Thus, when possible compression is suspected during testing, given that proximity of the course or distortion of the coronary is seen

- at the time of balloon inflations, a conservative approach is recommended.
6. When short length of the conduit or MPA raises concern for the potential risk of occlusion of pulmonary artery side branches with Melody Valve™ implantation, the use of open cell design stents at the time of pre-stenting can be most helpful. Even though these may have a higher recoil rate, they allow for strut dilation and reopening of a pulmonary artery branch (Figure 13) if overlapped by the stent.
7. If covered stents of appropriate sizes were readily available for implantation, it is likely that the use of the Melody Valve™ could be expanded to conduits of less than 16 mm in original diameter, as covered stent implantation would minimize the risk of conduit tear.

*As the experience with the Melody Valve™ continues to grow, its applications expand. Several non-conventional indications have*

*emerged as outlined above. Off-label use of existing PPV stents via hybrid and intraoperative implantation may benefit a select group of high-risk patients whose comorbidities render traditional surgical valve replacement unacceptable.<sup>21,23, 28</sup>*

## References

1. Lurz P, Coats L, Khambadkone S, Nordmeyer J, Boudjemline Y, Schievano S, Muthurangu V, Lee TY, Parenzan G, Derrick G, Cullen S, Walker F, Tsang V, Deanfield J, Taylor AM, Bonhoeffer P. Percutaneous pulmonary valve implantation: impact of evolving technology and learning curve on clinical outcome. *Circulation*. 2008;117(15):1964-1972.
2. Kanter KR, Budde JM, Parks WJ, Tam VK, Sharma S, Williams WH, Fyfe DA. One



## Update in Congenital Heart Management

*Immediately preceding the World Congress of Cardiology*  
 April 17, 2012; Jumeriah Beach Hotel, Dubai, UAE  
 For more information contact Alan Weisman at  
[aweisman@childrensnational.org](mailto:aweisman@childrensnational.org) or call +1-202-476-2728

## SAVE THE DATE

### Course Directors:

Richard Jonas, MD and Gerard Martin, MD

**Faculty:** Charles Berul, MD; Richard Levy, MD;  
 Craig Sable, MD and David Wessel, MD






Figure 13 A-C: (A) Spot cine performed in a patient following stenting of a stenotic right ventricle to pulmonary artery conduit. Extensive pulmonary artery stenting had been performed in both left (black arrow) and right (asterix) pulmonary artery. The conduit stent overlaps the takeoff of the right pulmonary artery (white arrow). (B) After sequential balloon angioplasties with progressively larger balloons the proximal right pulmonary artery is dilated with a 16 mm Altas balloon without waist. The open cell design stent allows for expansion of the stent strut without major difficulty. (C) Following Melody Valve™ implantation (black arrow), a main pulmonary artery (asterix) angiogram demonstrates no significant pulmonary valve insufficiency and open flow pattern into the right pulmonary artery which had no pressure gradient (white arrow).

- hundred pulmonary valve replacements in children after relief of right ventricular outflow tract obstruction. *Ann Thorac Surg.* 2002;73(6):1801-1806; discussion 1806-1807.
3. Bielefeld MR, Bishop DA, Campbell DN, Mitchell MB, Grover FL, Clarke DR. Reoperative homograft right ventricular outflow tract reconstruction. *Ann Thorac Surg.* 2001;71(2):482-487; discussion 487-488.
4. Tweddell JS, Pelech AN, Frommelt PC, Mussatto KA, Wyman JD, Fedderly RT, Berger S, Frommelt MA, Lewis DA, Friedberg DZ, Thomas JP, Jr., Sachdeva R, Litwin SB. Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. *Circulation.* 2000;102(19 Suppl 3):III130-135.
5. Askovich B, Hawkins JA, Sower CT, Minich LL, Tani LY, Stoddard G, Puchalski MD. Right ventricle-to-pulmonary artery conduit longevity: is it related to allograft size? *Ann Thorac Surg.* 2007;84(3):907-911; discussion 911-902.
6. Peng LF, McElhinney DB, Nugent AW, Powell AJ, Marshall AC, Bacha EA, Lock JE. Endovascular stenting of obstructed right ventricle-to-pulmonary artery conduits: a 15-year experience. *Circulation.* 2006;113(22):2598-2605.
7. Bouzas B, Kilner PJ, Gatzoulis MA. Pulmonary regurgitation: not a benign lesion. *Eur Heart J.* 2005;26(5):433-439.
8. Miyazaki A, Yamamoto M, Sakaguchi H, Tsukano S, Kagisaki K, Suyama K, Ohuchi H, Kurosaki K, Yagihara T, Yamada O. Pulmonary valve replacement in adult patients with a severely dilated right ventricle and refractory arrhythmias after repair of tetralogy of fallot. *Circ J.* 2009;73(11):2135-2142.
9. Adamson L, Vohra HA, Haw MP. Does pulmonary valve replacement post repair of tetralogy of Fallot improve right ventricular function? *Interact Cardiovasc Thorac Surg.* 2009;9(3):520-527.
10. Bonhoeffer P, Boudjemline Y, Saliba Z, Merckx J, Aggoun Y, Bonnet D, Acar P, Le Bidois J, Sidi D, Kachaner J. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. *Lancet.* 2000;356(9239):1403-1405.
11. Bonhoeffer P, Boudjemline Y, Saliba Z, Hausse AO, Aggoun Y, Bonnet D, Sidi D, Kachaner J. Transcatheter implantation of a bovine valve in pulmonary position: a lamb study. *Circulation.* 2000;102(7):813-816.
12. McElhinney DB, Hellenbrand WE, Zahn EM, Jones TK, Cheatham JP, Lock JE, Vincent JA. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. *Circulation.* 2007;115(5):507-516.
13. Coats L, Bonhoeffer P. Trans-catheter Pulmonary Valve Implantation: A Decade of Technology. *Congenital Cardiology Today.* 2011;14: 14-19.
14. Schievano S, Coats L, Migliavacca F, Norman W, Frigiola A, Deanfield J, Bonhoeffer P, Taylor AM. Variations in right ventricular outflow tract morphology following repair of congenital heart disease: implications for percutaneous pulmonary valve implantation. *J Cardiovasc Magn Reson.* 2007;9(4):687-695.
15. Lurz P, Gaudin R, Taylor AM, Bonhoeffer P. Percutaneous pulmonary valve implantation. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu.* 2009;112-117.
16. Nordmeyer J, Lurz P, Khambadkone S, Schievano S, Jones A, McElhinney DB, Taylor AM, Bonhoeffer P. Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation: acute and 1-year outcomes. *Heart.* 2007;97(2):118-123.
17. Demkow M, Biernacka EK, Spiewak M, Kowalski M, Siudalska H, Wolski P, Sondergaard L, Misko J, Hoffman P, Ruzyllo W. Percutaneous pulmonary valve implantation preceded by routine pre-stenting with a bare metal stent. *Catheter Cardiovasc Interv.* 2007;77(3):381-389.
18. Capelli C, Taylor AM, Migliavacca F, Bonhoeffer P, Schievano S. Patient-specific reconstructed anatomies and computer simulations are fundamental for selecting medical device treatment: application to a new percutaneous pulmonary valve. *Philos Transact A Math Phys Eng Sci.* 2007;368(1921):3027-3038.
19. Khambadkone S, Nordmeyer J, Bonhoeffer P. Percutaneous implantation of the pulmonary and aortic valves: indications and limitations. *J Cardiovasc Med (Hagerstown).* 2007;8(1):57-61.
20. Momenah TS, El Oakley R, Al Najashi K, Khoshhal S, Al Qethamy H, Bonhoeffer P. Extended application of percutaneous pulmonary valve implantation. *J Am Coll Cardiol.* 2009;53(20):1859-1863.
21. Bacha EA, Marshall AC, McElhinney DB, del Nido PJ. Expanding the hybrid concept in congenital heart surgery. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu.* 2007;146-150.
22. Robb JD, Harris MA, Minakawa M, Rodriguez E, Koomalsingh KJ, Shuto T, Shin DC, Dori Y, Glatz AC, Rome JJ, Gorman RC, Gorman JH, 3rd, Gillespie MJ. Melody valve implantation into the branch pulmonary arteries for treatment of pulmonary insufficiency in an ovine model of right ventricular outflow tract dysfunction



- following tetralogy of Fallot repair. *Circ Cardiovasc Interv.* 4(1):80-87.
23. Gillespie MJ, Dori Y, Harris MA, Sathanandam S, Glatz AC, Rome JJ. Bilateral branch pulmonary artery melody valve implantation for treatment of complex right ventricular outflow tract dysfunction in a high-risk patient. *Circ Cardiovasc Interv.* 4(4):e21-23.
  24. Roberts PA, Boudjemline Y, Cheatham JP, Eicken A, Ewert P, McElhinney DB, Hill SL, Berger F, Khan D, Schranz D, Hess J, Ezekowitz MD, Celermajer D, Zahn E. Percutaneous tricuspid valve replacement in congenital and acquired heart disease. *J Am Coll Cardiol.* 58(2):117-122.
  25. Tanous D, Nadeem SN, Mason X, Colman JM, Benson LN, Horlick EM. Creation of a functional tricuspid valve: novel use of percutaneously implanted valve in right atrial to right ventricular conduit in a patient with tricuspid atresia. *Int J Cardiol.* 144(1):e8-10.
  26. Eicken A, Fratz S, Hager A, Vogt M, Balling G, Hess J. Transcatheter Melody valve implantation in "tricuspid position" after a Fontan Bjork (RA-RV homograft) operation results in biventricular circulation. *Int J Cardiol.* 142(3):e45-47.
  27. Hasan, BS, McElhinney, DB, Brown DW, Cheatham JP, Vincent JA, Hellenbrand WE, Jones TK, Zhan EM, Lock JE. Short-Term Performance of the Transcatheter Melody Valve in High-Pressure Hemodynamic Environments in the Pulmonary and Systemic Circulations. *Circ Cardiovasc Interv.* 2011; 4: 615-620.
  28. Simpson KE, Huddleston CB, Foerster S, Nicholas R, Balzer D. Successful subxyphoid hybrid approach for placement of a melody percutaneous pulmonary valve. *Catheter Cardiovasc Interv.* 78(1):108-111.
  29. Weber B, Emmert MY, Behr L, Brokopp C, Frauenfelder T, Kretschmar O, Falk V, Hoerstrup SP. Fetal trans-apical stent delivery into the pulmonary artery: prospects for prenatal heart-valve implantation. *Eur J Cardiothorac Surg.*
  30. Boone RH, Webb JG, Horlick E, Benson L, Cao QL, Nadeem N, Kiess M, Hijazi ZM. Transcatheter pulmonary valve implantation using the Edwards SAPIEN transcatheter heart valve. *Catheter Cardiovasc Interv.* 75(2):286-294.
  31. Metzner A, Iino K, Steinseifer U, Uebing A, de Buhr W, Cremer J, Lutter G. Percutaneous pulmonary polyurethane valved stent implantation. *J Thorac Cardiovasc Surg.* 139(3):748-752.
  32. Schievano S, Taylor AM, Capelli C, Coats L, Walker F, Lurz P, Nordmeyer J, Wright S, Khambadkone S, Tsang V, Carminati M, Bonhoeffer P. First-in-man implantation of a novel percutaneous valve: a new approach to medical device development. *EuroIntervention.* 5(6):745-750.
  33. Feinstein JA, Kim N, Reddy VM, Perry SB. Percutaneous pulmonary valve placement in a 10-month-old patient using a hand crafted stent-mounted porcine valve. *Catheter Cardiovasc Interv.* 2006;67(4): 644-649.

## CCT



*Sara M. Trucco, MD*  
*Assistant Professor, Pediatrics*  
*University of Pittsburgh School of Medicine*  
*Children's Hospital of Pittsburgh*  
*4401 Penn Ave.*  
*Faculty Pavilion*  
*Pittsburgh PA 15204 USA*  
*(P) 412-692-5540; (F) 412-692-5138*  
*sara.trucco@chp.edu*



## Corresponding Author

*Jacqueline Kreutzer, MD, FACC, FSCAI*  
*Associate Professor of Pediatrics,*  
*University of Pittsburgh School of Medicine*  
*Director Cardiac Catheterization*  
*Laboratory*  
*Children's Hospital of Pittsburgh of UPMC*  
*Children's Hospital Dr.,*  
*45th and Penn*  
*Heart Center, 5th Floor*  
*Faculty Pavilion*  
*Pittsburgh PA 15201 USA*  
*(P): 412-692-8763 (F): 412-692-5138*  
*jacqueline.kreutzer@chp.edu*



## Florida Hospital for Children

### Pediatric Cardiac Electrophysiologist Walt Disney Pavilion Orlando, Florida

The Walt Disney Pavilion at Florida Hospital for Children is searching for a dynamic pediatric cardiac electrophysiologist to join the pediatric cardiology team as we develop a Regional Congenital Heart Program. This start up, fully-funded program would be built on collaboration, innovation, clinically credible volumes, leading outcomes, teaching and research.

The fully integrated, comprehensive congenital heart team would include: inpatient and outpatient cardiology, ECHO cardiography, fetal cardiology, interventional cardiology, 24/7 cardiac intensivists, pediatric cardiac anesthesiology, a full surgical team, a brand new bi-plane cath lab, and a state-of-the-art pediatric cardiovascular ICU.

Florida Hospital for Children is the only children's hospital among our statewide network of 22 hospitals with over 35 subspecialties.

Physician requirements include: Board Certification by the American Board of Pediatrics and certification/eligibility by the sub-board of Pediatric Cardiology, prior experience with a pediatric open heart program with fellowship training and experience in pediatric cardiac electrophysiology and post operative care.

### Contact:

Jason Junker, Director  
 Physician Recruitment  
 Phone: (407) 200-2538  
[jason.junker@flhosp.org](mailto:jason.junker@flhosp.org)



International Children's Heart Foundation



## VOLUNTEER YOUR TIME!

We bring the skills, technology and knowledge to build sustainable cardiac programmes in developing countries, serving children regardless of country of origin, race, religion or gender.

[www.babyheart.org](http://www.babyheart.org)

# A perfect melody of compassionate hearts, innovative minds and skilled hands.

## Melody<sup>®</sup>

### TRANSCATHETER PULMONARY VALVE (TPV) THERAPY

Worldwide, over 3,000 congenital heart disease patients have benefited from Melody TPV therapy. We remain committed to providing innovative options for your clinical management of these patients over their lifetime.

Visit [www.Melody-TPV.com](http://www.Melody-TPV.com)  
and restore hope for your patients.



#### Melody<sup>®</sup> Transcatheter Pulmonary Valve Ensemble<sup>®</sup> Transcatheter Valve Delivery System

**Indications:** The Melody TPV is indicated for use in a dysfunctional Right Ventricular outflow Tract (RVOT) conduit ( $\geq 16$  mm in diameter when originally implanted) that is either regurgitant ( $\geq$  moderate) or stenotic (mean RVOT gradient  $\geq 35$  mm Hg).

**Contraindications:** None known.

#### Warnings/Precautions/Side Effects:

- DO NOT implant in the aortic or mitral position.
- DO NOT use if patient's anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22-Fr size introducer, or if there is significant obstruction of the central veins.
- DO NOT use if there are clinical or biological signs of infection including active endocarditis.
- Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
- To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.
- The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.

- If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.

Potential procedural complications that may result from implantation of the Melody device include: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, and pain at the catheterization site.

Potential device-related adverse events that may occur following device implantation include: stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, and hemolysis.

For additional information, please refer to the Instructions for Use provided with the product or call Medtronic at 1-800-328-2518 and/or consult Medtronic's website at [www.medtronic.com](http://www.medtronic.com).

Melody and Ensemble are trademarks of Medtronic, Inc.

**Humanitarian Device.** Authorized by Federal law (USA) for use in patients with a regurgitant or stenotic Right Ventricular Outflow Tract (RVOT) conduit ( $\geq 16$  mm in diameter when originally implanted). The effectiveness of this system for this use has not been demonstrated.



# Effect of Endotracheal Suctioning on Dynamic Lung Compliance after Manual Hyperinflation in Mitral Valve Replacement Surgery Patients

By Nizamuddin, MPT; Faizan Ahmed, MPT;  
Muhammed Abid Geelani, MD, MCH; Jamal  
Ali Moiz, MPT, PhD

## Abstract

**Objectives:** Mitral valve disease patients have reduced lung compliance due to the pathology of the disease itself. In addition to the disease, anesthesia, cardiopulmonary bypass and mechanical ventilation further reduce lung compliance. Endotracheal suctioning has been reported to produce decreased lung compliance and it is still widely practiced. Therefore, the objective of our study is to investigate the effect of endotracheal suctioning and manual hyperinflation (MHI) on dynamic lung compliance (C<sub>dyn</sub>) in mechanically ventilated mitral valve replacement surgery patients.

**Methods:** A prospective randomized control trial was conducted with a sample of 30 mechanically-ventilated patients who had undergone mitral valve replacement surgery. Both the experimental and control group underwent four sets of eight compressions of Manual Hyperinflation procedure at 10-12 breaths/min with 2:1 ratio at 40 cm H<sub>2</sub>O. The experimental group underwent tracheal suctioning for a maximum of 15 seconds after every eight compressions of hyperinflation. C<sub>dyn</sub>, heart rate (HR), PCO<sub>2</sub>, PaO<sub>2</sub> and SaO<sub>2</sub> were measured five minutes before, 1 minute after, and 30 minutes after (for experimental group only) an intervention.

**Results:** No significant ( $p > 0.05$ ) Between-group difference was observed for C<sub>dyn</sub> ( $p = 0.841$ ), HR ( $p = 0.846$ ), PCO<sub>2</sub> ( $p = 0.324$ ), PaO<sub>2</sub> ( $p = 0.450$ ) and SaO<sub>2</sub> ( $p = 0.718$ ) immediately after intervention. Within group analyses showed a non-significant increase in C<sub>dyn</sub> ( $p = 0.174$ ) and SaO<sub>2</sub> ( $p = 0.859$ ) and non-significant decrease in PCO<sub>2</sub> ( $p = 0.7$ ) and PaO<sub>2</sub> ( $p = 1.0$ ) immediately after intervention in the experimental group whereas, a significant increase in C<sub>dyn</sub> ( $p = 0.001$ ), HR ( $p = 0.0001$ ) and PaO<sub>2</sub> ( $p = 0.031$ ) was noted in the control group immediately after intervention and a non-significant increase in SaO<sub>2</sub> ( $p = 0.358$ ) and non-significant decrease in PCO<sub>2</sub> ( $p = 0.348$ ) immediately after intervention.

**Conclusions:** Manual hyperinflation, when performed with and without suction, with a pressure of 40 cm H<sub>2</sub>O on a group of post-mitral valve replacement surgery patients no deleterious effect on arterial blood gas value and dynamic lung compliance. Therefore, this study suggests that endotracheal suctioning in




Figure 1. Comparison of dynamic lung compliance.




Figure 2. Comparison of heart rate.




Figure 3. Comparison of PCO<sub>2</sub>.




Figure 4. Comparison of PaO<sub>2</sub>.

conjunction with manual hyperinflation does not produce any deleterious changes in dynamic lung compliance and oxygenation in mechanically ventilated mitral valve replacement surgery patients.

**Keywords:** Endotracheal suctioning; Manual hyperinflation; Dynamic lung compliance; Respiratory mechanics; Hemodynamics.

## Introduction

Mitral valve disease is frequently associated with various pathological changes in respiratory function such as: decreased lung volumes, diffusing capacity and decreased static and dynamic lung compliance.<sup>1</sup>

Chronic disease is especially associated with increased pulmonary vascular pressure which invariably reduces the lung compliance and increases airway resistance.<sup>2,3</sup> During cardiac surgery, the use of general anesthesia muscle paralysis, mechanical ventilation, thoracotomy and cardiopulmonary bypass further substantially influences lung function.<sup>1</sup> General

anesthesia has been reported to cause depression of mucociliary functioning resulting in decreased mucus clearance in the perioperative period.<sup>4</sup> Cardiopulmonary bypass has been reported to produce a significant decrease in dynamic and static lung compliance during perioperative and postoperative period.<sup>5,6</sup> Moreover, mechanically ventilated patients are incapable of removing secretion from their airway as the glottis cannot be closed for an effective cough. This has been the rationale behind the practice of applying routine endotracheal suctioning to these patients.<sup>7</sup> Although endotracheal suctioning has been reported to have many adverse effects, including reduced lung compliance, it is still widely practiced in intubated patients. The disconnection of a patient from the ventilator during open-tracheal suctioning allows pressure to fall to atmospheric pressure,<sup>7,8</sup> which invariably reduces lung volume resulting in further decrease in lung compliance.<sup>9</sup> In mechanically

Table 1. Demographic Data					
Characteristics	Mean $\pm$ Std. Deviation (SD) (n=30)	MHI + Suction (n=15)	MHI (n=15)	t	p
Age (years)	29.73 $\pm$ 9.38	31.07 $\pm$ 10.33	28.40 $\pm$ 8.47	0.773	0.446
Height (meters)	1.58 $\pm$ 0.06	58.67 $\pm$ 5.86	157.53 $\pm$ 5.70	0.537	0.596
Weight (Kg)	43.30 $\pm$ 7.3	42.40 $\pm$ 5.88	44.20 $\pm$ 8.64	-0.67	0.510
BMI (Kg/m <sup>2</sup> )	17.275 $\pm$ 2.46	3.80 $\pm$ 0.49	3.68 $\pm$ 0.63	0.61	0.549
Cardiopulmonary bypass time (minutes)	82.10 $\pm$ 28.04	88.67 $\pm$ 31.55	75.53 $\pm$ 23.26	1.29	0.205

Table 2. Between-Group Comparison				
Variables	MHI Suctioning	MHI	t-test	
	Mean $\pm$ SD	Mean $\pm$ SD	t	p
Cdyn BL	25.57 $\pm$ 4.87	25.97 $\pm$ 6.25	-0.189	0.851
Cdyn 1 min	26.84 $\pm$ 5.58	27.29 $\pm$ 6.38	-0.203	0.841
HR BL	108.53 $\pm$ 18.19	111.73 $\pm$ 18.44	-4.78	0.0636
HR 1 min	117.20 $\pm$ 18.89	118.47 $\pm$ 16.53	-0.195	0.846
PCO <sub>2</sub> BL	34.17 $\pm$ 5.72	35.74 $\pm$ 6.08	-0.730	0.471
PCO <sub>2</sub> 1 min	33.17 $\pm$ 4.59	35.21 $\pm$ 6.38	-1.004	0.324
PaO <sub>2</sub> BL	217.53 $\pm$ 24.46	215.71 $\pm$ 47.47	0.132	0.896
PaO <sub>2</sub> 1 min	214.20 $\pm$ 36.85	224.80 $\pm$ 38.84	0.450	0.450
SaO <sub>2</sub> BL	99.41 $\pm$ 0.52	99.30 $\pm$ 1.12	0.740	0.740
SaO <sub>2</sub> 1 min	99.55 $\pm$ 0.35	99.47 $\pm$ 0.77	0.718	0.718

ventilated patients suction is always performed after chest physiotherapy and/or after a manual hyperinflation session so as to clear a larger amount of secretion from airways. However, both manual hyperinflation and suctioning produces an alteration in respiratory mechanics in addition to the effects of cardiopulmonary bypass and anesthesia in these patients. The combined effects of both the techniques on static lung compliance have been well-documented, but the effects on dynamic compliance have not been demonstrated. Some studies suggest a decrease in static lung compliance<sup>8,10,12</sup> while others suggest an increase in static lung compliance.<sup>4,11</sup> In contrast to static lung compliance very limited studies can be found on dynamic lung compliance. Most of the studies on dynamic lung compliance, were conducted on a pediatric population and reported a decrease in dynamic lung compliance after suctioning.<sup>10,12,13</sup>

Only a few studies have been reported on the effect of suctioning on dynamic lung compliance in adults and even lesser studies are found on combined effect of manual hyperinflation and endotracheal suction. There is almost no study that can be found on the effect of endotracheal suction and manual hyperinflation on mitral valve replacement surgery patients. Therefore,

the present study is intended to determine whether suction and manual hyperinflation improves or diminishes the lung compliance in those mitral valve disease patients who are already having reduced lung compliance due to disease, which is further reduced during anesthesia, cardiopulmonary bypass and mechanical ventilation.

## Methods

### Design

The study was a prospective, pre-test post-test control group, interventional, randomized study.

### Procedure

The approval of the study was obtained by the board of studies of the institution. A day before surgery patients scheduled for mitral valve surgery were approached and explained about the type and nature of study. All the agreed subjects were requested to sign the informed consent form preoperatively. Three to four hrs after a standardized surgical procedure a detailed evaluation was performed on the mechanically ventilated mitral valve replacement surgery patients. Then a total

sample of 30 subjects was selected according to inclusion and exclusion criteria.

The inclusion criterion consists of post-mitral valve replacement surgery patients, Intubated and mechanically-ventilated patients with continuous mandatory ventilation (CMV) mode, age group 20-50 years. Subjects with arterial oxygen saturation  $\leq$  90%, associated lung pathology e.g. COPD and acute Respiratory Distress Syndrome (ARDS).<sup>11</sup> Unstable blood pressure<sup>11</sup> (MAP  $<$  75 mmHg), requiring high respiratory support<sup>11</sup> (FiO<sub>2</sub>  $\geq$  0.7 and PEEP  $>$  10cm H<sub>2</sub>O), air leakage,<sup>14</sup> severe bronchospasm<sup>14</sup> were excluded. All the patients recruited in the study were ventilated with a Siemens Servo 300 Ventilator on volume control mode with FiO<sub>2</sub> of 50% after surgery.

The selected patients were then randomized into two groups, Group-A (MHI+Suctioning) or Group-B (MHI), equally. On the day of measurement, each patient was positioned in supine and undisturbed for 15 minutes prior to data collection. All sterile measures were carefully taken before touching the patient. Five minutes before the intervention the first data (baseline) was collected. At the end of five minutes, relevant intervention, according to the group assigned, was delivered to the patient. Group-A patients were delivered manual hyperinflation along with suctioning according to standard protocol using a two-liter sterile ShineBall® (Taiwan) self-inflating resuscitator bag and a sterile FG-12 suction catheter respectively. The suction pressure was set to -150 mmHg. Group-B patients received only manual hyperinflation using a two-liter sterile resuscitator bag as an intervention. The second set of data was collected one minute after the completion of the respective intervention. After collecting the second data control group (Group-B), patients were given endotracheal suctioning to remove the collected secretion in the trachea. The third set of data was collected 30 minutes after the intervention in an experimental group only, and couldn't be collected for Group-B patients, as the same sample got contaminated due to the suctioning procedure performed after collecting second set of data (1 minute after intervention).

## Protocol

### Group A: Manual Hyperinflation and Endotracheal Suctioning

Four sets of eight bag compressions, connected to 100% oxygen (15 L/min), with both hands were delivered during each

Harboring Hearts Housing Foundation, Inc.  
333 West 52nd St., Suite 700  
New York, NY 10019  
info@harboringhearts.org | (212) 255-8371

[www.HarboringHearts.org](http://www.HarboringHearts.org)

**Harboring Hearts**  
Giving Hope to Hearts Everywhere



Table 3. Within-Group Comparison of the Experimental (MHI+Suctioning) Group								
Variables	BL (n=15)	1 Min Post	30 Min Post	ANOVA		Post Hoc Significance (p)		
	Mean $\pm$ SD	Mean $\pm$ SD	Mean $\pm$ SD	F	p	BL to 1 Min	1 Min to 30 m	BL To 30 Min
Cdyn	25.575 $\pm$ 4.87	26.842 $\pm$ 5.58	26.59 $\pm$ 4.84	3.13	0.077	0.174	1.0	0.063
HR	108.53 $\pm$ 18.19	117.20 $\pm$ 18.89	106.60 $\pm$ 17.48	27.69	0.0001	0.0001	0.427	0.0001
PCO <sub>2</sub>	34.17 $\pm$ 5.72	33.167 $\pm$ 4.59	32.99 $\pm$ 4.45	1.05	0.379	0.70	0.467	1.0
PaO <sub>2</sub>	217.53 $\pm$ 24.46	214.2 $\pm$ 36.85	219.47 $\pm$ 29.63	0.63	0.088	1.0	1.0	0.803
SaO <sub>2</sub>	99.41 $\pm$ 0.52	99.553 $\pm$ 0.35	99.43 $\pm$ 0.58	0.75	0.490	0.859	1.0	1.0

Table 4. Within-Group Comparison of Control (MHI) Group			
Variables	BL	1 Min	p
	Mean $\pm$ SD	Mean $\pm$ SD	
Cdyn	25.96 $\pm$ 6.52	27.2 $\pm$ 6.38	.001
HR	111.73 $\pm$ 18.44	118.47 $\pm$ 16.53	.0001
PCO <sub>2</sub>	35.74 $\pm$ 6.08	35.2 $\pm$ 6.38	.348
PaO <sub>2</sub>	215.71 $\pm$ 47.47	224.80 $\pm$ 38.84	.031
SaO <sub>2</sub>	99.30 $\pm$ 1.12	99.47 $\pm$ 0.77	.358

manual hyperinflation session. The rate of inflation was 10-12 breaths/minute with inspiratory: expiratory ratio of 2:1. A pressure manometer was attached to the self-inflating resuscitator bag and each compression was delivered to a peak airway pressure of 40 cm H<sub>2</sub>O, aiming to maximize lung volume and followed by a two-second inspiratory pause and then a quick release of the bag to enhance the expiratory flow rate. Tracheal suctioning was applied after delivery of eight manual hyperinflation breaths. The duration of each pass of suction was limited to 15 seconds. Tracheal suctioning was performed once per set of eight bag compressions.<sup>11</sup>

#### Group B: Manual Hyperinflation

Four sets of eight bag compressions, connected to 100% oxygen (15 L/min), with both hands were delivered during each manual hyperinflation session. The rate of inflation was 10-12 breaths/minute with inspiratory: expiratory ratio of 2:1. A pressure manometer was attached with the self inflating resuscitator bag and each compression was delivered to a peak airway pressure of 40 cmH<sub>2</sub>O, aiming to maximize lung volume and followed by a two-second inspiratory pause and then a quick release of the bag to enhance the expiratory flow rate. After every eight compressions, the patient was reconnected to ventilator for one minute then, again eight compressions was delivered.<sup>11</sup>

#### Statistical Analysis

The complete data was analyzed using SPSS 15.0 for Windows® software. First a detailed description was obtained using descriptive statistics and then the data was analyzed to find any baseline differences. An Independent t-Test was used to analyze the Between-group differences. A repeated measure ANOVA was performed for analysis of within subject differences. The repeated measure of time was baseline, one minute after and 30 minutes post-intervention. The repeated measure test was applied only to the experimental group, as there was no post-30 minutes data for the control group. The paired t-Test was used for analysis of subject differences between baseline and one-minute post-intervention (immediately) in the control group.

#### Results

##### Sample

A total sample of thirty subjects (n=30) with age group between 20-50 years with mitral valve replacement surgery was used for the study.

##### Patients Characteristics

The demographic data and baseline differences in the data for all the subjects are mentioned in Table 1. There were no statistically significant differences found

between the baseline data of the two groups. The sample contained a greater number of women 66.67% (n=20) than men 33.33% (n=10). Thirty-six point sixty-seven percent (n=11) of total patients were implanted with bioprosthetic valves, and the remaining 63.33% (n=19) of subjects were implanted with mechanical valve.

#### Outcome Measures

Between-group comparisons showed no statistically significant (p>0.05) difference between the variables of two groups (MHI + Suctioning and MHI group). The dynamic compliance showed a non-significant (p=0.841) improvement immediately (1 minute) after intervention (p=0.841). The heart rate (p=0.85), PCO<sub>2</sub> (p=0.32), PaO<sub>2</sub> (p=0.45) and SaO<sub>2</sub> (p=0.71) also showed a non-significant (p>0.05) change Between-group analyses of immediate post-intervention data.

Within-group analysis of the experimental group showed a non-significant (p= 0.174) increase (4.97%) in dynamic lung compliance from baseline (25.575  $\pm$  4.873) (Mean  $\pm$ SD) to 1 minute post-intervention (26.842  $\pm$  5.582). Similarly, 1 minute post-intervention data when compared with 30 minute post (26.59  $\pm$  4.839) intervention data also resulted in non-significant (p=1.0) decrease (0.93%) in dynamic lung compliance. Baseline data compared with 30 minute post-intervention data also showed non-significant (p=0.063) improvement (3.989%) in dynamic lung compliance, whereas, the control group (MHI), showed a significant (p=0.001) increase (5.1%) in dynamic lung compliance from baseline (25.962  $\pm$  6.250) to 1 minute post-intervention (27.286  $\pm$  6.379).

The heart rate in the experimental group showed a significant (p=0.0001) increase (8.018%) from baseline (108.53  $\pm$  18.197) to 1 minute post-intervention (117.20  $\pm$  18.895).



Barth Syndrome  
Foundation

## The Barth Syndrome Foundation

P.O. Box 974, Perry, FL 32348

Tel: 850.223.1128

info@barthsyndrome.org

www.barthsyndrome.org

**Symptoms:** Cardiomyopathy, Neutropenia, Muscle Weakness, Exercise Intolerance, Growth Retardation



## Pediatric Cardiologist

The Section of Pediatric Cardiology at Brody School of Medicine at East Carolina University in Greenville, North Carolina is recruiting a BE/BC pediatric cardiologist with expertise in non-invasive imaging. The physician should be proficient in transthoracic, transesophageal, and intracardiac echocardiography of the fetal, pediatric, and adult congenital patient. Interest or experience in nuclear cardiology and magnetic resonance imaging of congenital cardiac patients is desired but not required.

The physician will join a 5-person division providing care to a population of 1.3 million people in 29 counties in eastern North Carolina. The section provides inpatient, outpatient, outreach clinic, electrophysiologic, interventional catheterization, and surgical support for the pediatric and adult congenital cardiac patient. The Department of Pediatrics consisting of 13 divisions provides a diverse primary and subspecialty support for the pediatric population. Outpatient pediatric/adult congenital cardiac services are provided at East Carolina Heart Institute at East Carolina University as well as at 9 outreach clinic sites. Inpatient pediatric/adult congenital cardiac services are provided at the 142 bed Children's Hospital of Eastern North Carolina as well as at the 120 bed East Carolina Heart Institute at Vidant Medical Center.

The successful candidate should have a record of teaching and/or research, excellent clinical skills, BC in Pediatrics and BE/BC in Pediatric Cardiology, must be able to obtain a license to practice medicine in North Carolina, must be granted medical staff privileges at Vidant Medical Center, must be approved to practice through ECU Physicians, and receive medical liability insurance coverage through our carrier.

Applicants should submit a candidate profile online ([www.jobs.ecu.edu](http://www.jobs.ecu.edu)) including Curriculum Vitae, Letter of Interest, and list of three references (noting contact information). East Carolina University is an Equal Opportunity/Affirmative Action University that Accommodates individuals with disabilities.

### For more information contact:

Charlie J. Sang, Jr., M.D.  
Section Head  
Section of Pediatric Cardiology  
Brody School of Medicine at East Carolina University  
East Carolina Heart Institute  
115 Heart Drive  
Greenville, NC 27834  
[sangc@ecu.edu](mailto:sangc@ecu.edu)  
(252) 744-5601

Baseline data, when compared with 30 minute post-intervention ( $106.60 \pm 17.484$ ) data, resulted in non-significant ( $p=0.427$ ) decrease (1.75%) in heart rate. Similarly, 1 minute post-intervention data with 30 minute post-intervention data resulted in a significant ( $p=0.0001$ ) decrease (9.04%) in heart rate. The control group showed a significant ( $p=0.0001$ ) increase (6.03%) in heart rate.

Within-group analysis of the experimental group showed a non-significant ( $p=0.70$ ) decrease (2.926%) in  $PCO_2$  between baseline ( $34.167 \pm 5.717$ ) to 1 minute post-intervention ( $33.167 \pm 4.596$ ) data. Similarly, comparison between 1 minute post-intervention data with 30 minute post-intervention ( $32.99 \pm 4.448$ ) data and baseline data with 30 minute post-intervention data also showed a non-significant decrease ( $p=0.467$ ) (3.436%), ( $p=1.0$ ) (0.525%) in  $PCO_2$  respectively. The control (MHI) group also showed a non-significant ( $p=0.348$ ) decrease (1.4%) in  $PCO_2$  between baseline ( $34.16 \pm 5.717$ ) and 1 minute post intervention data ( $33.167 \pm 4.596$ ).

A non-significant ( $p=0.70$ ) decrease (2.93%) in  $PCO_2$  was found between baseline ( $34.167 \pm 5.717$ ) to 1 minute post-intervention ( $33.167 \pm 4.596$ ) data in the experimental group. One minute post-intervention data compared with 30 minute post-intervention ( $32.99 \pm 4.448$ ) data, also showed a non-significant ( $p=0.467$ ) decrease (3.45%) in  $PCO_2$ . The comparison between the baseline data and 30 minute post-intervention data, also resulted in non-significant ( $p=1.0$ ) decrease (0.52%) in  $PCO_2$ .

In the control (MHI) group comparison between baseline and 1 minute post-intervention data resulted in a non-significant ( $p=0.348$ ) decrease (1.4%) in  $PCO_2$  from  $34.16 \pm 5.717$  to  $33.167 \pm 4.596$  was found respectively. The experimental group in the Within-group analysis, showed a non-significant ( $p=1.0$ ) decrease (1.51%) in  $PaO_2$  baseline ( $217.53 \pm 24.462$ ) to 1 minute post-intervention ( $214.20 \pm 36.848$ ) data. One minute post-intervention data compared with 30 minute post-intervention ( $219.47 \pm 29.63$ ) data also resulted in a non-significant ( $p=0.803$ ) increase (2.4%) in  $PaO_2$ . Similarly, baseline compared with 30 minute post-intervention data also resulted in a non-significant ( $p=1.0$ ) increase (0.92%) in  $PaO_2$ . The control group showed a significant ( $p=0.031$ ) increase (4.22%) in  $PaO_2$  from baseline ( $215.71 \pm 47.47$ ) to 1 minute post ( $224.80 \pm 38.84$ ) intervention data.

$SaO_2$  showed a non-significant ( $p=0.859$ ) increase (0.15%) from baseline ( $99.407 \pm .518$ ) to 1 minute post-intervention ( $99.553 \pm .354$ ) data in the experimental group. One minute post-intervention data compared with 30 minute post-intervention ( $99.43 \pm .58$ ) data resulted in a non-significant ( $p=1.0$ ) decrease in  $SaO_2$ . The decrease was 0.12%. Comparison between baseline data and 30 minute post-intervention data also showed a non-significant ( $p=1.0$ ) increase (0.03%) in  $SaO_2$ . In the control group, the comparison resulted in a non-significant ( $p=0.358$ ) increase (0.17%) in  $SaO_2$  from baseline ( $99.300 \pm 1.118$ ) to 1 minute post-intervention ( $99.473 \pm 0.770$ ).

### Discussion

To our knowledge this is the first study to investigate the effect of ET suctioning and MHI on dynamic lung compliance in sedated, paralyzed mitral valve replacement surgery patients during volume control mode of ventilation on the day of surgery.

Both of the groups showed a non-significant increase in dynamic lung compliance from the baseline values. Between-group comparison of



11615 Hesby Street  
N. Hollywood, CA 91601  
Tel: 818.754.0312 Fax: 818.754.0842  
[www.campdelcorzan.org](http://www.campdelcorzan.org)



dynamic lung compliance showed a non-significant change which shows that, suction along with MHI does not produce any adverse effects on pulmonary function; it does, however, produce a similar change in dynamic lung compliance as is produced by manual hyperinflation alone. The probable reason for this might be the dominating effect of manual hyperinflation on the suctioning. Since the suction catheter was passed only for once per eight bag compression the adverse effect of suctioning would have been less on pulmonary function and the application of manual hyperinflation with a larger-than-normal tidal volume breath, together with an inspiratory pause, may have facilitated collateral ventilation and effective recruitment of alveoli, thereby, preventing the adverse effect of suctioning and resulting in increased dynamic lung compliance.<sup>11</sup>

Within-group comparison of the experimental group showed an improvement of 4.97% in dynamic lung compliance which was statistically insignificant in immediately post-intervention duration. The result of the present study was comparable with the study by Morrow et al, in 2007<sup>12</sup> where, when recruitment maneuver was performed after ET suction, a non-significant increase in dynamic lung compliance was observed immediately after intervention. Five minutes after an ET suctioning procedure was used on pediatric patients, MHI was performed. The researchers reported that the decrease in dynamic lung compliance from suctioning resolved spontaneously with an unchanged ventilator setting. In the present study, MHI was given immediately in conjunction with suctioning. Therefore, the effect produced was not due to ventilator settings. The present study is also supported by the study by Blattner et al. in 2008<sup>4</sup> where, when MHI was applied following suctioning a significant increase in static lung compliance was reported in fifty-five myocardial revascularization patients. In another similar study by Siu-Ping et al in 2005,<sup>11</sup> when manual hyperinflation and suction was applied on fifteen adult mechanically-ventilated pneumonia patients, a significant increase (22%) in static lung compliance was observed. In another similar study by Patman et al in 2000,<sup>15</sup> when manual hyperinflation alone was administered to mechanically ventilated CABG patients, they showed a significant increase (15%) in static lung compliance. All the above studies showed an increase in lung compliance.

In contrast to the above studies, some have reported a decrease in dynamic lung compliance after the application of intervention. A study by Morrow et al, in 2006,<sup>13</sup> where when, suction alone was administered to mechanically-ventilated, seventy-eight pediatric patients a significant decrease in dynamic lung compliance was reported. In an animal study by Almgren et al, in 2004,<sup>8</sup> when suction alone was administered to subjects with pressure controlled and volume controlled ventilation, a significant decrease in dynamic lung compliance was reported. The suction procedure in the present study might have caused a decrease in lung compliance in the ventilated patients. Since the suction catheter was introduced only once per eight bag compressions, the fall in lung compliance might have been less, and the effect of manual hyperinflation might have overcome the adverse effect of suctioning; therefore, the immediate improvement in dynamic lung compliance which occurred in the present study might have been caused by the manual hyperinflation procedure. Furthermore, none of the patients in the present study produced large amount of secretions, and only minimal amounts of secretions were removed during the manual hyperinflation and suction interventions. This minimal change in the airway clearance and the additive effect of manual hyperinflation might have been the additional probable reason for a non-significant improvement in the dynamic lung compliance in 1 minute post-



## Pediatric Cardiologists

The Division of Pediatric Cardiology at the University of Utah School of Medicine and based at Primary Children's Medical Center is recruiting board eligible/board certified pediatric cardiologists with major interests in 1) Heart Transplant/Heart Failure and 2) Adult Congenital Heart Disease. The Pediatric Cardiologists will join a 25-member division and established Heart Transplant and Adult Congenital Heart Disease Programs. There will be protected time and mentoring available within the Division for clinical research. The Division has a very active clinical research program and is one of the participating centers in the Pediatric Heart Disease Clinical Research Network funded by the NIH.

The successful candidates will receive a faculty appointment at the University of Utah on the clinical or tenure track. Rank will be dependent on qualifications. The University of Utah offers an excellent benefits package that includes 20.2% retirement contributions that vest immediately, and excellent health care choices. Salt Lake City is a diverse major metropolitan area with outstanding restaurants, arts and music. Recreation is unparalleled with 6 ski resorts within 30 minutes and 5 national parks within an easy 4 hour drive. It is serviced by a convenient international airport with direct flights to most major cities.

To read more about each opportunity and to apply, please go to:

### Heart Transplant/Heart Failure Position

<http://utah.peopleadmin.com/postings/13074>

### Adult Congenital Heart Disease Position

<http://utah.peopleadmin.com/postings/8177>

For additional information, please contact Lloyd Y. Tani, MD:

[lloyd.tani@imail.org](mailto:lloyd.tani@imail.org).

*The University of Utah is an EO/AA employer and educator. Minorities, women, and persons with disabilities are strongly encouraged to apply. Veterans preference. Reasonable accommodations provided. For additional information: <http://www.regulations.utah.edu/humanResources/5-106.html>.*

*The University of Utah Health Sciences Center is a patient focused center distinguished by collaboration, excellence, leadership, and respect. We value candidates who are committed to fostering and furthering the culture of compassion, collaboration, innovation, accountability, diversity, integrity, quality, and trust that is integral to the mission of the University of Utah Health Sciences Center.*



**Fetal, Perinatal and  
Neonatal Cardiology**  
SYMPOSIUM  
State of the Art and New Frontiers

## 2012 International Symposium on Pediatric Cardiology

April 10 to 13, 2012; Rimrock Resort Hotel, Banff, Alberta, Canada

Phone: 780.436.0983 ext. 227; Fax: 780.437.5984

[www.buksa.com/PedsCard2012/](http://www.buksa.com/PedsCard2012/)

## PEDIATRIC HEART FAILURE/ TRANSPLANT CARDIOLOGIST OPPORTUNITY



The Departments of Pediatrics at the University of Louisville School of Medicine and Kosair Children's Hospital are recruiting for a medical director of heart failure and cardiac transplantation for the Congenital Heart Center at Kosair Children's Hospital in Louisville, Ky.

The primary responsibilities for this position focus on directing and expanding current clinical programs in pediatric heart failure and transplantation to include collaborating with very successful clinical programs in adult heart failure, mechanical assist devices and transplantation. The Kosair Charities Pediatric Heart Research Program at the Cardiovascular Innovation Institute in Louisville and a broad array of basic science research programs at the University of Louisville provide outstanding research infrastructure and collaborative opportunities, with active programs in basic science and translational research involving tissue engineering, stem cells and ventricular assist devices.

An excellent multi-year compensation package is available, commensurate with expertise. Contact Christopher L. Johnsrude, M.D., chief of pediatric cardiology, at [cljohn02@louisville.edu](mailto:cljohn02@louisville.edu) or (502) 852-3876, or Amanda R. Bailey, physician recruitment manager, Norton Physician Services, at (502) 439-5144 or [amanda.bailey@nortonhealthcare.org](mailto:amanda.bailey@nortonhealthcare.org).



Kosair Children's Hospital (a part of Norton Healthcare) and the University of Louisville are Affirmative Action, Equal Opportunity, Americans with Disabilities employers, committed to diversity. In that spirit, we seek applications from a broad variety of candidates.

intervention (immediately). In the post 30 minute period the dynamic lung compliance demonstrated a fall of 0.93% from 1 minute post-intervention to 30 minute post-intervention in the experimental group. This fall in dynamic lung compliance is also statistically non-significant. The probable cause of fall in the lung compliance in the post-30 minute period may be due to a cascade fall in the number of reinflated alveoli and the supine position.

heart rate also showed a non-significant change when compared for Between-Group analyses. Both the group showed increase in heart rate from the baseline, but the difference between the groups was non-significant. Within-group comparison of experimental group showed a significant increase (8.02%) in heart rate in immediate post-intervention duration. The result of the present study can be comparable to a study by Lee et al, in 2001 where, they reported a significant increase in heart rate immediately after first pass and second pass of open suctioning procedure in fourteen adult ventilated patients.<sup>16</sup> The result of the present study is also consistent with the study results found by Stone et al, in 1991, where a statistically significant increase in heart rate was observed from baseline after the three lung hyperinflation-suctioning sequences in CABG patients.<sup>17</sup> This indicates that suctioning along with manual hyperinflation increases heart rate. The probable cause for an increase in heart rate in the present study may be the activation of sympathetic receptors present in large airways, and the discomfort that occurred due to the suctioning procedure.<sup>18</sup> At the 30 minute post-intervention, the heart rate reduced (9.04%), significantly returning to the baseline value in experimental group. The probable reason for reduction in the heart in the present study, may be due to the relief from suction discomfort. Involvement of parasympathetic activity and vagal stimulation, may be the other valid cause of decrease in heart rate.<sup>19,20</sup>

Between-group analysis of PCO<sub>2</sub> resulted in a non-significant change in the immediate post-intervention period. This indicates that both the group results in similar amounts of CO<sub>2</sub> washout in immediate post-intervention duration. The PCO<sub>2</sub> value did not alter significantly after any intervention, indicating that minute ventilation remained adequate.<sup>21</sup> Within-group comparison of experimental group also resulted in a non-significant decrease (2.93%) in PCO<sub>2</sub> at 1 minute post-intervention and 30 minute post-intervention (3.43%). Since the number of breaths for MHI was kept constant (10-12 breath/min), the minute ventilation might have remained adequate. This is in agreement with the attempts made to maintain alveolar ventilation by decreasing the respiratory rate and increasing the tidal volume for hyperinflation. Maintained ventilation of the alveoli during hyperinflation may have prevented a marked washout of CO<sub>2</sub> from the blood. The present finding is supported by Paratz et al. where PCO<sub>2</sub> did not alter post-MHI as alveolar ventilation was maintained.<sup>22</sup>

PaO<sub>2</sub> also showed a non-significant difference between the groups at 1 minute post-intervention. Although the difference in PaO<sub>2</sub> is non-significant, the improvement was found to be greater in control (MHI) group. This may be due to the fact that MHI might have recruited the atelectatic lung units and might have created a better room for gaseous exchange.<sup>23</sup> Between-group comparison also showed a non-significant increase in PaO<sub>2</sub> in experimental group at 1 minute post (1.52%) and at 30 minute post-intervention (2.47%). This indicates that suction did not produced any adverse effect on PaO<sub>2</sub> value, rather that PaO<sub>2</sub> value increased 30 minute after intervention in the experimental. Studies have suggested that suction, when applied in mechanically-ventilated patients, produces a significant decrease in PaO<sub>2</sub> levels in the blood.<sup>8,20,24</sup> In the present study, a decrease in PaO<sub>2</sub> was non-significant, which means the fall in PaO<sub>2</sub> was less, which indicate that lung function has not much deteriorated after suctioning procedure.

The application of MH may utilize intercommunicating channels, or collateral ventilation within the lungs, to facilitate the mobilization of secretions and the recruitment of atelectatic lung units, thereby, improving FRC.<sup>25</sup> This might be the cause for better gaseous exchange. Since both suctioning and manual hyperinflation were used in the present study, the manual hyperinflation might have masked the adverse effect of suctioning by opening the collateral channel in the lungs and improving the alveolar recruitment and gaseous exchange.

No statistically significant difference in SaO<sub>2</sub> was found between the two groups. Within-group comparison of SaO<sub>2</sub> also showed a non-significant increase at 1 minute post (0.15%) and at 30 minute post-intervention (0.12%). Under normal condition the value of PaO<sub>2</sub> is ≥ 95 mmHg and value of SaO<sub>2</sub> is ≥ 97%. The maximum value of saturation under normal



condition is 100%. In the present study all the patients have a saturation value above 97%. Therefore, the change observed in patients was very small and it was clinically insignificant. Since the value of PaO<sub>2</sub> affects the saturation a non-significant change in PaO<sub>2</sub> may be the other probable cause for non-significant change in SaO<sub>2</sub>.

Limitation of the study includes the inability to use a more accurate method of measuring dynamic lung compliance in mechanically ventilated patients. The 30 minute post-intervention data could not be collected in the control group, as suctioning was required to be done immediately after intervention in order to remove collected mucus in the central airway. Another limitation includes the lack of fixed dosimetry for suctioning procedure.

Further study is required to be done in various groups of population, including double-valve replacement surgery patients. The sample size used in the study was insufficient to generalize the result therefore a study with a larger sample size is needed to be done. Furthermore, study with different protocol of manual hyperinflation and suctioning is required to be done. This study has found the short-term effects of manual hyperinflation and suction on dynamic lung compliance, long-term effect of the same is required to be done in future.

## Conclusion

In conclusion, our results show that manual hyperinflation when performed with and without suction with a PIP of 40 cm H<sub>2</sub>O on a group of post-mitral valve replacement surgery patients has no deleterious effect on arterial blood gas value; dynamic lung compliance was found. Therefore, this study suggests that endotracheal suctioning in conjunction with manual hyperinflation does not produce any deleterious changes in dynamic lung compliance and oxygenation in mechanically ventilated mitral valve replacement surgery patients.

## References

- Hachenberg T, Tenling A, Hansson HE, Tydén H, Hedenstierna G. The Ventilation-Perfusion Relation and Gas Exchange in Mitral Valve Disease and Coronary Artery Disease Implications for Anesthesia, Extracorporeal Circulation, and Cardiac Surgery. *Anesthesiology* 1997; 86: 809-817.
- Palmer WH, Gee JBL, Mills C, Bates DV. Disturbances of Pulmonary Function in Mitral Valve Disease. *canad med assoc j*, 1963;89:744-750.
- Auchincloss J H, Robert G, Eich RH. The pulmonary diffusing capacity in congenital and rheumatic heart disease. *Circulation* 1959; 19:232-41.
- Blattner C, Guaragna JC, Saadi E. Oxygenation and static compliance is improved immediately after early manual hyperinflation following myocardial revascularization a randomized controlled trial. *Australian Journal of Physiotherapy* 2008; 54: 173-178.
- Hedenstierna G. Alveolar collapse and closure of airways: regular effects of anesthesia. *Clin Physiol & Func Im* 2003; 23:123-129.
- Mahmoud AS, Burhani MS, Hannef AA, Jamjoom AA, Al-Githmi IS, Baslaim GM. Effect of modified ultra-filtration on pulmonary function after CPB. *Chest* 2005;128:3447-3453.
- Van de Leur JP, Zwaveling JM, Loeff BG, van der Schans CP. Endotracheal suctioning versus minimally invasive airway suctioning in intubated patients: a prospective randomised controlled trial. *Intensive Care Med* 2003;29:426-432.
- Almgren B, Wickerts CJ, Heinonen E, Högman M. Side Effects of Endotracheal Suction in Pressure- and Volume-Controlled Ventilation. *Chest* 2004;125:1077-1080.
- Maggiore SM, Lellouche J, Pigeot J, Taille S, Deye N, Durrmeyer X. Prevention of Endotracheal Suctioning-induced Alveolar De-recruitment in Acute Lung Injury. *Am Jnl Of Resp And Crit Care Med* 2003;167:1215-1224.
- Brandstater B, Muallem M. Atelectasis following tracheal suction in infants. *Anesthesiology* 1969;31:468-473.
- Choi JSP, Jones AYM. Effects of manual hyperinflation and suctioning on respiratory mechanics in mechanically ventilated patients with ventilator-associated pneumonia, *Australian Journal of Physiotherapy* 2005;51:25-30.
- Morrow B, Futter Margent A. A recruitment maneuver performed after endotracheal suction does not increase dynamic compliance in ventilated pediatric patients a randomized controlled trial, *Australian Journal of Physiotherapy* 2007;53: 163-169.
- Morrow B, Futter M, Argent A. Effect of endotracheal suction on lung dynamics in mechanically-ventilated pediatric patients. *Australian Journal of Physiotherapy* 2006;52:121-126.
- Donna Frownfelter, Elizabeth Dean. Principles and practice of cardiopulmonary physical therapy. 3rd ed. Mosby, 1996.
- Jones A, Hutchinson R, Oh T. Effects of bagging and percussion on total static compliance of the respiratory system. *Physiotherapy* 1992; 78:661-666.
- Lee CK, Ng KS, Tan SG, Ang R. Effect of different endotracheal suctioning systems on cardiorespiratory parameters of ventilated patients. *Ann Acad Med Singapore* 2001; 30:239-44.
- Stone KS, Talaganis SA, Preusser B, Gonyon DS. Effect of lung hyperinflation and endotracheal suctioning on heart rate and rhythm in patients after coronary artery bypass graft surgery. *Heart Lung* 1991;20:443-50.
- Clark AP, Winslow EH, Tyler DO, White KM. Effects of endotracheal suctioning on mixed venous oxygen saturation and heart rate in critically ill adults. *Heart Lung* 1990;19:552-7.
- Segar JL, Merrill DC, Chapleau MW, Robillard JE. Hemodynamic changes during endotracheal suctioning are mediated by increased autonomic activity. *Pediatr Res*. 1993;33:649-52.
- Gunderson LP, Stone KS, Hamlin RL. Endotracheal suctioning-induced heart rate alterations. *Nurs Res*. 1991;40:139-43.
- Hodgson C, Denehy L, Ntoumenopoulos G, Santamaria J, Carroll S. An investigation of the early effects of manual lung hyperinflation in critically ill patients. *Anaesth Intensive Care*. 2000;28:255-61.
- Paratz J, Lipman J, McAuliffe M. Effect of Manual Hyperinflation on Hemodynamics, Gas Exchange, and Respiratory Mechanics in Ventilated Patients. *Journal of Intensive Care Medicine* 2002;17: 317-324.
- Patman S, Jenkins S, Stiller K. Manual hyperinflation--effects on respiratory parameters. *Physiother Res Int*. 2000;5:157-71.
- Wood CJ. ET Suctioning a literature review. *Intensive Crit Care Nurs*. 1998;14:124-36.
- Andersen JB, Qvist J, Kann T. Recruiting collapsed lung through collateral channels with positive end-expiratory pressure. *Scand J Respir Dis*. 1979 ; 60:260-6.

**CCT**

Nizamuddin, MPT  
Pushpanjali Crosslay Hospital  
Vaishali, U.P., India  
Tel: +919720074509  
drnizam83@gmail.com

Faizan Ahmad  
Assistant Professor  
Department of Rehabilitation Sciences  
Faculty of Allied Health Sciences  
Jamia Hamdard (Deemed University)  
New Delhi, India

Muhammed Abid Geelani, MS, MCH  
Professor CTVS  
G.B. Panth Hospital  
New Delhi, India

## Corresponding Author:

Jamal Ali Moiz, MPT, (PhD)  
Assistant Professor  
Centre for Physiotherapy and  
Rehabilitation Sciences  
Jamia Millia Islamia (Central University)  
New Delhi 110025, India  
Tel : +919968202281  
jmoiz@jmi.ac.in

# Medical News, Products and Information

## Unique Cardiac Training Gives NewYork-Presbyterian/Columbia Doctor Ability to Treat Heart Patients With Hybrid Approach

Patients with coronary artery disease -- blockages of the vessels that feed the heart -- can be treated in a number of ways. With their doctor, they decide on the best course of action: surgery, stent placement or medication. Sometimes, a combination of these is the best approach.

Hybrid cardiac revascularization procedures, a combination of bypass and stenting, can reduce the stress of surgery, speeding recovery and potentially improving outcomes.

Dr. Mathew Williams, one of the only physicians in the world trained as both a cardiothoracic surgeon and interventional cardiologist, performs the hybrid procedures at NewYork-Presbyterian Hospital/Columbia University Medical Center.

"Because of my training, I am particularly aware of the benefits and risks of bypass and stenting, and can recommend a customized treatment plan that works best for the patient whether it's one or the other, or both," says Dr. Williams, Surgical Director of Cardiovascular Transcatheter Therapies at NewYork-Presbyterian Hospital/Columbia University Medical Center and Assistant Professor of Surgery in Medicine at Columbia University College of Physicians and Surgeons.


The hybrid approach usually involves minimally invasive surgery using the internal mammary artery to bypass the most important coronary branch, the left anterior descending (LAD). This is followed by a stenting procedure in which tiny metal scaffolds are inserted through an artery in the patient's groin and positioned to prop open the other blocked arteries.

The next step is for both procedures to be performed concurrently. This is possible in a specially-equipped hybrid operating room at the Vivian and Seymour Milstein Family Heart Center at NewYork-Presbyterian Hospital/Columbia University Medical Center.

Dr. Williams also offers a hybrid approach for other cardiac procedures, including treatment for aneurysms and aortic valve replacement. NewYork-Presbyterian/Columbia also offers hybrid procedures for neurology patients.

"Hybrid procedures are an emerging trend. This is good news for our patients, especially as more physicians receive dual training in surgery and interventional techniques," says Dr. Craig Smith, Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia University Medical Center and chairman of the Department of Surgery at Columbia University College of Physicians and Surgeons.

"The hybrid approach shows how multidisciplinary collaboration can directly benefit the patient," says Dr. Allan Schwartz,



**PedCath8**  
now certified for the NCDR  
**IMPACT Registry™**

**Upgrade Today!**

NCDR compliant cath data is harvested transparently from the PedCath8 report.

PedCath8 provides an expanded, searchable INTERNAL database.

Includes every required IMPACT field.

Automatic error checking meets stringent ACC standards.

No more paper forms.

**Scientific Software Solutions** 434.293.7661  
www.PedCath.com  
Support@PedCath.com



ACHA - 6757 Greene Street, Suite 335 - Philadelphia, PA, 19119  
P: (888) 921-ACHA - F: (215) 849-1261

*A nonprofit organization which seeks to improve the quality of life and extend the lives of congenital heart defect survivors.*

<http://achaheart.org>



## Pediatric Cardiologist East Tennessee

Tri-City Pediatric Cardiology is seeking immediate placement for a pediatric cardiologist to join their two physician group in Tri-Cities Tennessee.

Must be BE/BC, skilled in general pediatric cardiology, all aspects of noninvasive diagnostic modalities including transthoracic, transesophageal and fetal Echo and have a liking/training in diagnostic and interventional cardiac catheterization and cardiac MRI.

The physician will share equal call with minimal inpatient responsibilities on call and 80% of time spent in one of our 3 offices which are all equipped with state of the art Echo machines and staffed with pediatric trained full time Echo techs.

Attractive compensation package including relocation expenses, competitive salary based on experience and comprehensive benefits package. Partnership track available for the ideal candidate.

**Contact Jason Freeman, Wellmont Health System at**  
[jason.freeman@wellmont.org](mailto:jason.freeman@wellmont.org)  
**Call 423-230-8270**  
**fax CV to 423-230-8502**



## JUNE MEDICAL MEETING FOCUS

**Cardiostim 2012**  
**18<sup>th</sup> World Congress**  
**Cardiac Electrophysiology & Cardiac Techniques**  
 June 13-16, 2012; Nice, France  
[www.cardiostim.com](http://www.cardiostim.com)

### CARDIOSTIM Team:

Philippe Ritter (Bordeaux, FRA); Pierre Bordachar, Stéphane Garrigue, Sylvain Reuter, Frédéric Sacher (Bordeaux, FRA); Mark O'Neill (London, GBR), Vincent Probst (Nantes, FRA); David HAYES (Rochester, USA), Douglas ZIPES (Indianapolis, USA), Jean-Claude DAUBERT (Rennes, FRA), Jean-Jacques BLANC (Brest, FRA). See website for faculty list.

### In Collaboration With:

European Heart Rhythm Association; Société Française de Cardiologie; European Society of Cardiology; Heart Rhythm Society (HRS); World Society of Arrhythmias / ICPES; International Society for Holter and Noninvasive Electrocardiology; Groupe Français d'Electrophysiologie et de Stimulation Cardiaque de la Société Française de Cardiologie; Club Français des Technologies Biomédicales de la SEE (Société des Electroniciens et des Electriciens); Sociedad Asociación Civil Argentina de Estimulación Cardíaca; Asian-Pacific Society of Cardiology; Brazilian Society of Cardiology; Latin-American Society of Pacing and Electrophysiology (SOLAECE); Artificial Cardiac Electrostimulation Department of the Brazilian Cardiac Surgery Group (DECA); Associazione Italiana di Aritmologia e Cardiostimolazione; Mediterranean Society of Pacing and Electrophysiology; The RETAC Group; Japanese Heart Rhythm Society (JHRS).

### CME Credits:

EHRA SESSIONS at CARDIOSTIM 2012 are currently under review for accreditation by the European Board for Accreditation in Cardiology (EBAC) for external CME credits. The accreditation results will be announced online and in the final program

### Program Overview:

- European Heart Rhythm Association (EHRA) Program
- Basic Electrophysiology
- Complex Electrophysiology and Ablation Techniques
- Novel Approaches to Apply Mechanistic Insights to Complex Human Arrhythmias
- Treatments for Atrial Fibrillation
- Advances and Controversies in Atrial Fibrillation (ACAF)
- Noninvasive Electrocardiology
- Educational Symposium of International Society for Holter and Noninvasive Electrocardiology (ISHNE)
- Main Trials in the Management of Atrial Fibrillation
- Acute Cardiac Care: Management of SCD
- Pacing, ICDs and CRT
- Leads

### Associate Symposia Include:

- Cardiostim / HRS Joint Session
- Cardiopace
- Vaso Vagal Syncope
- Geriatric Cardiology
- Asia Pacific Cardiostim Symposium
- Palpitations
- Fetal Cardiology Symposium
- Pediatric Cardiac Electrophysiology
- Cardiostim-JHRS Joint Session
- Syncope
- ICE Program
- Italian Cardiostim Symposium
- EPIC Alliance; Industry Symposia

*Visit the website for program detail and complete list of international faculty*

**SPECIALTY  
REVIEW IN** **Pediatric  
Cardiology**  
**SEPTEMBER 10-14, 2012 • CHICAGO**

**A BOARD REVIEW COURSE PRESENTED BY**  
**American Academy of Pediatrics Section on Cardiology & Cardiac Surgery**  
**— in collaboration with —**  
**Society of Pediatric Training Program Directors**

*Discounts for early registration and AAP members available.*

[www.aap.org/sections/cardiology/pediatric\\_cardiology/2012](http://www.aap.org/sections/cardiology/pediatric_cardiology/2012)

Cardiologist-in-Chief at New York-Presbyterian Hospital/Columbia University Medical Center and the Harold Ames Hatch Professor of Medicine Columbia University College of Physicians and Surgeons at Columbia University College of Physicians and Surgeons.

Dr. Mathew Williams received more than 14 years of medical training, beginning with his medical school training at Columbia University College of Physicians and Surgeons, followed by a residency in general surgery at UCLA. He returned to Columbia for a research fellowship in cardiothoracic surgery. At New York-Presbyterian/Columbia, he completed a residency in general surgery, followed by fellowships in cardiothoracic surgery and interventional cardiology.

### Big Breakthrough for the Tiniest Hearts

A novel feeding device developed at the University of Pennsylvania School of Nursing may decrease the risk of failure to thrive (FTT), which currently affects half of all newborns with congenital heart defects even after their surgical lesions are corrected.

Professor and nurse practitioner Barbara Medoff-Cooper, PhD, CRNP, of Penn Nursing invented a device that analyzes an infant's ability to organize feeding by sucking, swallowing, and breathing effectively. This device, developed in collaboration with Penn bioengineers, allows healthcare professionals to assess infants at risk for dysfunctional feeding and poor weight gain as often seen in both premature infants and infants with complex congenital heart disease. The data also can be correlated with growth or developmental problems that may occur during the first year of life.

"Feeding actually speaks loudly to us about the brain," says Dr. Medoff-Cooper. "If a child is feeding well, it gives us one fewer major issue to worry about. Conversely, even a full-term infant who is not feeding well is at high risk for developmental problems."

Dr. Medoff-Cooper conducted the first comprehensive evaluation of feeding difficulties in infants with complex congenital heart defects. Her work has demonstrated that feeding behaviors can predict developmental outcomes in high-risk infants because of the complicated interplay of movements and physiologic responses needed in the feeding process. The premise of her work is that feeding effectiveness corresponds to how well infants will achieve other developmental milestones.

The University of Pennsylvania School of Nursing is one of the premier research institutions in nursing, producing new knowledge in geriatrics, pediatrics, oncology, quality-of-life choices, and other areas. Researchers here consistently receive more research funding from the National Institutes of Health than any other private nursing school, and many Master's programs are ranked first in the country. This year, faculty, students, alumni, and staff celebrate 125 years of nursing at Penn.

## Pediatric Cardiology Electrophysiologist - Assistant Professor

THE UNIVERSITY OF CALIFORNIA, SAN DIEGO, DEPARTMENT OF PEDIATRICS (<http://www-pediatrics.ucsd.edu>) AND CHILDREN'S SPECIALISTS OF SAN DIEGO (<http://childrensspecialists.com>) are committed to academic excellence and diversity within the faculty, staff, and student body and are jointly recruiting a Pediatric Electrophysiologist for the unified Division of Pediatric Cardiology at Rady Children's Hospital, San Diego. This 442-bed facility serves as a major regional tertiary care hospital for children and is the major teaching facility for the Department of Pediatrics of the UCSD School of Medicine.

The Electrophysiologist position is a unique opportunity to join an exceptional Electrophysiology, Pacing and Adult Congenital Electrophysiology Program in San Diego. The successful candidate must have specific training and experience in pediatric cardiac electrophysiology and should possess the qualifications for academic appointment at the rank of Assistant Professor. The academic series will be determined based on the background and qualifications of the successful candidates. Candidates must be Board Certified or eligible in Pediatric Cardiology and licensed or licensable to practice medicine in the State of California. This appointment will require administrative capabilities, excellent skills in clinical care and teaching, and clinical research development and accomplishment. Preference will be given to candidates with experience in equity and diversity with experience teaching, mentoring, research, life experiences, or service towards building an equitable and diverse scholarly environment.

The Division provides a full range of Pediatric Cardiology services. It currently has ten pediatric cardiologists, three cardiothoracic surgeons, and an ACGME approved fellowship program. The Division supports a program with more 400 surgical procedures yearly and 100 electrophysiology procedures. Extensive opportunities to perform clinical, epidemiologic or basic science research exist at UCSD and Children's Hospital, San Diego.

Salary will be commensurate with qualifications and based on University of California pay scales.

Review of applications will begin April 30, 2012 and continued until the position is filled.

Please apply via <http://apol-recruit.ucsd.edu/> to the following job opening:

PEDIATRICS  
Assistant Professor (RCHSD Cardiology) (10-387)

For consideration, you will be asked to submit:

- a letter of interest,
- a curriculum vitae including the list of publications and professional activities,
- a statement of teaching experience,
- the names and email addresses of 3-5 references, and
- a separate personal statement summarizing past or potential contributions to diversity (see <http://facultyequity.ucsd.edu/Faculty-Applicant-C2D-Info.asp> for further information).

*AA-EOE: UCSD is an Affirmative Action/Equal Opportunity Employer with a strong institutional commitment to excellence through diversity.*



China California Heart Watch

[www.chinacal.org](http://www.chinacal.org)

Robert Detrano MD, PhD, President  
Cardiology and Professor of Radiological Science and Medicine  
University of California at Irvine  
19 Mistral Lane  
Irvine, CA 92617  
USA Phone: 949-737-1637; China Phone: 86-86096061  
Email: [robert@chinacal.org](mailto:robert@chinacal.org)

*Dedicated to understanding and relieving problems of heart disease and health care in rural China*





The Children's Hospital of Illinois and University of Illinois College of Medicine at OSF Saint Francis Medical Center are Seeking Pediatric Cardiologists in Peoria and Rockford, Illinois

**Peoria** - The new pediatric cardiologist will join a well-established team of 7 pediatric Cardiologists with 30 plus years of success in the region. In addition to general pediatric cardiology, opportunities are focused on those interested in echocardiography, fetal echocardiography, and adult congenital heart disease. Professional components include in-patient rotation coverage, general cardiology clinic coverage and in-patient/out-patient echocardiography. Scholarly and research interests are highly desirable, along with experience in teaching medical students and residents. The candidate must be board-certified or board-eligible in pediatric cardiology and will report to the Medical Director, Pediatric Cardiology.

**Rockford** - A BC/BE noninvasive pediatric cardiologist is desired to join 3 well established pediatric cardiologists in the Rockford branch of the Congenital Heart Center (CHC) system. The practice has been a stable source of quality pediatric cardiology care in the community for more than 20 years. The candidate should be skilled in all facets of echocardiography. Skills in fetal cardiology are desirable. The qualified individual will be part of the CHC which includes an additional 8 cardiologists at the Peoria campus. There is a direct clinical and academic relationship between the two groups.

The University of Illinois is an Affirmative Action/Equal Opportunity employer.

**Stacey Morin, OSF Pediatric Cardiology  
CHOI**

Ph: 309-683-8354 or

800-232-3129 press 8; Fax: 309-683-8353

E-mail: [stacey.e.morin@osfhealthcare.org](mailto:stacey.e.morin@osfhealthcare.org)

Website: [www.childrenshospitalofil.org](http://www.childrenshospitalofil.org)

# PICS-AICS

Pediatric and Adult Interventional Cardiac Symposium

# CHICAGO

MARRIOTT CHICAGO DOWNTOWN

APRIL 15-18, 2012

## COURSE DIRECTORS:

Ziyad M. Hijazi, MD, John P. Cheatham, MD,  
Carlos Pedra, MD & Thomas K. Jones, MD

- **Focusing on the Latest Advances in Interventional Therapies for Children and Adults** with congenital and structural heart disease, including the latest technologies in devices, percutaneous valves, stents and balloons.
- **Imaging Session** dedicated to the field of imaging in congenital and structural cardiovascular interventional therapies.
- **Daily Breakout Sessions** dedicated to the care of adults with congenital and structural heart disease.
- **Hot Daily Debates** between cardiologists and surgeons on controversial issues in intervention for congenital and structural heart disease.
- **Breakout Sessions** for cardiovascular nurses and CV technicians.
- The popular session of **"My Nightmare Case in the Cath Lab"**
- **Oral & Poster Abstract Presentations**
- **Live Case Demonstrations** featuring approved and non-approved devices, valves, and stents, and will be transmitted daily from cardiac centers from around the world. During these live cases, the attendees will have the opportunity to interact directly with the operators to discuss the management options for these cases.

**Accreditation:** Rush University Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Rush University Medical Center designates this live activity for a maximum of 35 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only credit commensurate with the extent of their participation in the activity.

**Abstract Submission Deadline is December 1, 2011.**

For registration and abstract submission go to [www.picsymposium.com](http://www.picsymposium.com)



## CONGENITAL CARDIOLOGY TODAY

© 2012 by Congenital Cardiology Today (ISSN 1554-7787-print; ISSN 1554-0499-online). Published monthly. All rights reserved.

824 Elmcraft Blvd., Rockville, MD 20850 USA

## Publishing Management:

- Tony Carlson, Founder & Senior Editor - [TCarlsonmd@gmail.com](mailto:TCarlsonmd@gmail.com)
- Richard Koulbanis, Publisher & Editor-in-Chief - [RichardK@CCT.bz](mailto:RichardK@CCT.bz)
- John W. Moore, MD, MPH, Medical Editor - [JMoore@RCHSD.org](mailto:JMoore@RCHSD.org)

## Editorial Board:

Teiji Akagi, MD; Zohair Al Halees, MD; Mazeni Alwi, MD; Felix Berger, MD; Fadi Bitar, MD; Jacek Bialkowski, MD; Philipp Bonhoeffer, MD; Mario Carminati, MD; Anthony C. Chang, MD, MBA; John P. Cheatham, MD; Bharat Dalvi, MD, MBBS, DM; Horacio Faella, MD; Yun-Ching Fu, MD; Felipe Heusser, MD; Ziyad M. Hijazi, MD, MPH; Ralf Holzer, MD; Marshall Jacobs, MD; R. Krishna Kumar, MD, DM, MBBS; John Lamberti, MD; Gerald Ross Marx, MD; Tarek S. Momenah, MBBS, DCH; Toshio Nakanishi, MD, PhD; Carlos A. C. Pedra, MD; Daniel Penny, MD, PhD; James C. Perry, MD; P. Syamasundar Rao, MD; Shakeel A. Qureshi, MD; Andrew Redington, MD; Carlos E. Ruiz, MD, PhD; Girish S. Shirali, MD; Horst Sievert, MD; Hideshi Tomita, MD; Gil Wernovsky, MD; Zhuoming Xu, MD, PhD; William C. L. Yip, MD; Carlos Zabal, MD

*Statements or opinions expressed in Congenital Cardiology Today reflect the views of the authors and sponsors, and are not necessarily the views of Congenital Cardiology Today.*

## Camp Heartbeat 2012

Brainy Camp Association, A subsidiary of Children's National Medical Center

August 4-7, 2012; Massanetta Springs, VA


Contact: Sandra Cushner Weinstein, PT, LCSW-C Phone: 202-476-5142; [scushwei@childrensnational.org](mailto:scushwei@childrensnational.org)

[www.brainycamps.com](http://www.brainycamps.com)

*"For Children and Teens with Congenital Heart Disorders, Pacemakers, Arrhythmias and ICDs"*



Children's National  
Medical Center



**TINY HEARTS**

**inspired**

## **HYBRID LABS WITH ACCESS FOR BIG TEAMS.**

Fixing a heart from birth through adulthood takes big teams working together. So we examined the needs of leading clinicians when designing our hybrid solutions. The result: our Infinix™-i with 5-axis positioners and low profile detectors, stays out of the way, but right where needed, providing the best possible access to patients. To lead, you must first listen. [medical.toshiba.com](http://medical.toshiba.com)



[youtube.com/toshibamedical](http://youtube.com/toshibamedical)



[@ToshibaMedical](https://twitter.com/ToshibaMedical)